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PHENOTYPIC AND IMMUNOHISTOCHEMICAL CHARACTERIZATION OF 
CONDITIONAL KNOCKOUT MICE WITH A DELETION IN GLUTAMIC 
ACID DECARBOXYLASE (GAD) IN GPR88 CONTAINING NEURONS AND 
THE ROLE OF STRIATAL GAD IN L-DOPA INDUCED DYSKINESIA 
SAMANTHA LABAK 
ABSTRACT 
 Glutamic Acid Decarboxylase (GAD) is a rate-limiting enzyme responsible for 
synthesis of the inhibitory neurotransmitter GABA.  Dopaminergic denervation in 
rodents by unilateral injections of 6-OHDA or MPTP causes an increase in Gad67 
mRNA in the striatum, which is further exacerbated by administration of L-Dopa 
(Horvath et al., 2011; Katz et al., 2005 Bacci et al., 2002).  Denervation of nigrostriatal 
neurons is the key pathological hallmark of Parkinson’s disease, which results in 
hypokinetic movement and rigidity. Medium spiny projection neurons of the striatum 
comprise 95% of the neuronal population and utilize Gad67 (encoded by the Gad1 gene) 
for the synthesis of basal levels of GABA.  The contribution of Gad67 to GABA 
signaling in medium spiny projection neurons in the striatum has not been thoroughly 
understood in normal or Parkinsonian states.  Mice with a deletion in Gad67 in Gpr88 
expressing neurons were generated by crossing mice with a floxed exon 2 of Gad1 with 
mice expressing Cre recombinase under the control of the Gpr88 promoter.  The aim of 
this study was first, to characterize mice with a deletion in striatal Gad67 by 
immunohistochmical, electriophysiological and behavioral examination to determine 
whether Gad67 expression contributes to sensorimotor and learning tasks. And next, to 
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investigate whether a downregulation in striatal Gad67 would decrease dyskinesia and 
affect the impaired motor symptoms following dopaminergic denervation with a 
unilateral 6-OHDA lesion and subsequent treatment with L-Dopa.  In this study, neuronal 
Gpr88 expression was indicated by GFP reporter expression, which resulted from Cre-
mediated excision of exon 2 of the Gad1 gene.  Gpr88 expression was confirmed in the 
striatum, olfactory tubercle, cortex and brain stem.  Furthermore, Gpr88 was confined to 
striatonigral and striatopallidal MSNs in the striatum.  Additionally, Cre-mediated GFP 
reporter expression indicated that Gpr88 expression occurs throughout various brain 
regions, including the motor and visual areas of the cortex, amygdala, hippocampus and 
cerebellum during development.  The developmental expression of Gpr88 seems to be a 
highly regulated process that occurs throughout the brain.  In the conditional knockout 
mouse, deleting striatal Gad67 resulted in an upregualtion of Gad67 in the globus pallidus 
and downregulation in the substantia nigra.  The changes in Gad67 expression indicate 
the effects of inactivating GABAergic signaling in striatonigral and striatopallidal MSNs 
in the direct and indirect pathways.  Mice with a deletion in striatal Gad67 demonstrated 
compromised performance in spatial learning in the Morris water maze, suggesting that 
GABAergic striatal signaling in the direct and indirect pathways accounts for cue-based 
learning and spatial memory.  However, inactivation of GABAergic signaling in 
striatonigral and striatopallidal MSNs does not account for motor deficits such as 
bradykinesia, akinesia or hypokinesia in intact mice; instead it perpetuates hyperkinetic 
motor activity.  In the second experiment of this study, dopaminergic denervation by a 
unilateral 6-OHDA lesion induced bradykinesia and hypokinetic motor behavior, as 
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demonstrated by impaired performance in the rota-rod and pole test.  Additionally, L-
Dopa administration to 6-OHDA lesioned mice evoked abnormal involuntary movements 
(AIMs) to the same degree in all dyskinetic mice.  A deletion in striatal Gad67 did not 
decrease symptoms of dyskinesia, nor cause a lessening of motor impairment caused by 
dopaminergic denervation.  Complete inactivation of the indirect pathway is believed to 
limit the inhibition of unwanted actions and may perpetuate dyskinesia, even when 
striatonigral MSNs of the direct pathway are inactive.  
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INTRODUCTION 
 
Basal Ganglia 
The basal ganglia is a major neural structure made up of subcortical nuclei 
engaged in relaying and integrating input from cortical areas and thalamus (Lanciego et 
al., 2012; Delong and Wichmann, 2007).   Major functions attributed to the basal ganglia 
include voluntary motor control, learning and working memory, as well as eye 
movements, cognitive and emotional tasks.  The structures within basal ganglia are 
categorized in three groups (i) input nuclei (ii) output nuclei and (iii) intrinsic nuclei 
(Lanciegoet al., 2012).  The input nuclei include the caudate nucleus, putamen and 
nucleus accumbens (NAcc), which receive information from cortical, thalamic and nigral 
sources.  Output nuclei consist in the substantia nigra (SNr) and globus pallidus interna 
(GPi), which send information from the basal ganglia to the thalamus.  The subthalamic 
nucleus (STN), globus pallidus externa (GPe) and substantia nigra pars compacta (SNc) 
are considered intrinsic nuclei and are located between the input and output nuclei 
(Lanciegoet al., 2012).   
The largest structure of the basal ganglia is the striatum, which includes the 
caudate nucleus and putamen.  The striatum receives a significant portion of basal ganglia 
dopaminergic and glutamatergic input from all cortical areas and the thalamus, and sends 
inhibitory output to other components of the basal ganglia.  The circuits within the 
cortical-basal ganglia-thalamic circuit provide information for (i) voluntary motor 
responses (ii) predicting future events and (iii) shifting attention sets during movement 
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initiation and spatial working memory (Herero et al., 2002). The cortical-basal ganglia-
thalamic circuit provides a mechanism through which cortical, thalamic and basal ganglia 
structures relay information, which plays a role in learning and executing behaviors.  The 
separate but integrated pathways within the basal ganglia explain the varied symptoms 
seen in basal ganglia disease, such as the inability to execute specific behaviors or motor 
functions and adapt to internal and external cues (Herrero et al., 2002; Harber and 
Calzavara, 2009).      
Cortical-Basal Ganglia-Thalamic Circuits  
The cortical-basal ganglia-thalamic circuits involve the cortex, basal ganglia and 
thalamic relay nuclei.  Different cortical areas terminate in specific regions of the basal 
ganglia and thalamus to establish a functional organization for separate and parallel loops 
(Kelly et al., 2004).  The circuits are designed in accordance with the origin of cortical 
projections, including motor, oculomotor, prefrontal associative and limbic areas 
(DeLong and Wischmann, 2007; Goldman-Rakic and Porrino, 1985).  The circuits within 
the basal ganglia operate through direct input to the striatum, which is differentiated into 
dorsal and ventral basal ganglia circuits and interstriatal neurons (Herrero et al., 2002).  
The dorsal basal ganglia circuit includes the caudate and putamen of the dorsal striatum, 
which receives input from the neocortex and sensorimotor cortex.  The ventral basal 
ganglia circuit consists of the NAcc, which receives input from ortibitofrontal and limbic 
structures, as well as from the hippocampus and amygdala (Herrero et al., 2002).  
Thalamic relay nuclei play a dual role in basal ganglia function.  First, the thalamic nuclei 
relay basal ganglia output to the frontal cortex. Second, they provide direct feedback to 
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the striatum.  Thalamo-striatial connections provide reciprocal projections within the 
circuit and maintain functional distinctions between the striatal regions.  The sources of 
these connections are midline and intralaminar nuclei, which can be further broken down 
into groups of nuclei that are associated with specific regional connections (Smith et al., 
2004; Sadikot et al., 1992; Nakano et al,. 1990; Haber and Calzavara, 2009). Cortical and 
thalamic projections, along with their reciprocal connections within the motor cortico-
basal ganglia-thalamic circuit are organized and depicted in fig 1 (Haber and Calzavara, 
2009). 
 
Fig 1. Cortical-Striatal-Thalamic projections in the motor circuit.  This diagram 
depicts the premotor projections in the cortical-basal ganglia-thalamic circuits to 
demonstrate the functional link between regions of the cortex, thalamus and basal 
ganglia.  The caudal motora areas of the cortex (primary motor area, M1; caudal 
premotor cortex, PMcs; supplementary motor area, SMA; and caudal cingulate motor 
area, CMAc) mainly connect to the ventral thalamic nuclei VPLo and VLo.  The 
Dorsolateral and dorsocentral putamen regions receive input from the caudal motor 
cortex, VPLo and VLo projections.  Rostral motor areas of the cortex (rostral mremotor 
cortex, PMr; presupplementary motor area, PreSMA; and rostral cingulate motor area, 
CMAr) are mainly connected with the ventral thalamic nucleus VApc.  The dorsolateral 
caudate nucleus and rostral putamen receive efferent projections from the VApc and 
rostral motor areas of the cortex.  Additionally, both caudal and rostral motor areas and 
CMAc connect with the ventral thalamic nucleus VLc.  The dorsolateral caudate nucleus 
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receives input from the CLC and corresponding cortical areas. (Figure taken from Haber 
and Calzavara, 2009).   
 
Although the functional topography of the cortex is maintained in the basal 
ganglia and thalamus, integration between motor control, cognition and emotion input 
does occur.  The convergence of projections from different functional regions provides 
support for striatal involvement in learning and flexibility (Harber and Calzavara, 2009).  
There are two ways by which the parallel pathways integrate cortical input.  First, 
dendrites and axons cross functional boundaries, even though projections from the cortex 
often terminate in specific basal ganglia structures (Kolomiets et al., 2001).  Second, 
terminals converge at adjacent regions or in areas surrounding smaller basal ganglia 
structures.  The edges of functional regions are likely to process signals from other 
functional areas (Kolomiets et al., 2001).  The directional flow of information through 
converging projections allows for information to be channeled from the ventral striatum 
to the central striatum and finally, to the dorsal striatum to allow the convergence of 
limbic, cognitive and motor information (Harber and Calzavara, 2009).  The convergence 
of projections at functional junctions allows for information from cognitive and reward 
cortices to come together, which further perpetuates goal directed behavior and habit 
formation (Harber and Calzavara, 2009).   
Another layer of integration is provided by the thalamo-cortico-thalamic 
component of the basal ganglia circuit.  In the thalamo-cortico-thalamic circuit, the 
thalamus provides the one-way relay back to the cortex (Harber and Calzavara, 2009).  
Although the thalamus receives input from only the deep cortical layers, the thalamus 
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sends projections into the superficial, middle and deep cortical layers.  Thalamic 
projections allow information from higher cortical areas of the prefrontal cortex to 
integrate with rostral motor areas and primary motor areas that dictate execution of motor 
function (Harber and Calzavara, 2009).   
In conclusion, the organization of the cortico-basal ganglia-thalamic circuit 
provides the basic striatal function based on parallel, but integrated, pathways that 
operate through motor, cognitive and limbic inputs.  The cortico-basal ganglia-thalamic 
circuit was extensively reviewed by Haber and Calzavara to thoroughly explain the major 
mechanisms within the cortico-basal ganglia-thalamic circuit that contribute to normal 
basal ganglia function. 
    
Striatum 
The main input structure of the basal ganglia is the striatum.  The striatum is 
innervated by the dopaminergic nigrostriatal system and receives glutamatergic input 
from the corticostriatal system and thalamostriatal projections (Smith et al., 2004; Gerfen, 
1992).  The classical theory of dorso-ventral division of the stratum was proposed by 
Heimer and Wilson, which suggests that the striatum is divided into categorical and 
qualitative regions (Heimer and Wilson, 1975). The striatum is organized functionally by 
its corticostriatal projections into the motor, associative and limbic striatum in both 
primates and rodents (Parent and Hazarti, 1995; Joel and Weiner; 1994).  The functional 
subunits are delineated structurally into the dorsal and lateral striatum.  The dorsal 
striatum includes the caudate nucleus and putamen and is responsible for motor and 
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associative functions.  It is further divided in rodents into the medial (associative) and 
lateral (motor) aspects (Joel and Weiner; 2000).  The ventral striatum, or NAcc, consists 
of core and shell components and is responsible for limbic functions (Joel and Weiner; 
2000).   
However, there are not clear anatomical distinctions between the dorsal-ventral 
striatum.  Recent evidence challenges the classical view and suggests that there is a 
ventromedial-dorsolateral gradient of specialization in the striatum.  Task-dependent 
striatal activation in behavioral studies demonstrates gradient dependent signaling 
(Cerovic et al., 2013).  Additionally, a clear distinction between areas of the dorso-ventral 
striatum has not been distinguished histologically or immunohistochemically.  A 
ventromedial-dorsolateral gradient in the striatum provides for a convincing argument for 
the partial functional overlap between the dorsal and ventral striatum seen in learning and 
memory tasks (Cerovic et al., 2013).  Therefore, it is more appropriate to consider the 
divisions in the striatum as relative rather than absolute, as there are no sharp boundaries 
that divide the dorso-ventral striatum.  
Striatal afferent innervation 
The dorsal and ventral striatum are innervated by glutamatergic and dopaminergic 
afferent projections.  Glutamatergic afferent projections to the dorsal striatum are derived 
from the cortex and thalamus, while the NAcc receives inputs from limbic areas, 
including the prefrontal cortex, hippocampus and amygdala (Cerovic et al., 2013).  
Origins of dopaminergic afferents also differ between the dorsal and ventral striatum.  
The dorsal striatum is innervated by dopaminergic projections from the lateral substantia 
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nigra pars compacta (SNc), while dopaminergic projections to the ventral striatum 
originate in the ventral tegmental area (VTA) and medial SNc (Joel and Weiner, 2000).   
The dopaminergic innervation of the striatum was extensively reviewed by Joel and 
Weiner to compare the connections of the dopaminergic system in rats and primates and 
recognize the functional implications of the dopaminergic system in basal ganglia 
activity. 
Striatal efferent signaling  
Most striatal efferent signal transmission occurs via GABAergic medium spiny 
neurons (MSNs) that project to the GP, SN and internal palladium complex, while a small 
efferent population consists of cholinergic and GABAergic interneurons.  There are two 
different populations of MSNs in the striatum.  One population of MSNs is known as 
striatonigral, which is distinguished by the dopamine receptor D1 (DRD1), muscarine M4 
acetylcholine receptor, substance-P and preprodynorphin (PPD) (Gerfen and Surmeier 
2011; Gerfen et al., 1990; Gerfen and Young, 1988).  The second population of MSNs is 
known as striatopallidal, which is distinguished by the dopamine receptor D2 (DRD2), 
A2A adenosine receptor, and preproenkephalin (PPE) (Gerfen and Surmeier 2011; 
Gerfen et al., 1990; Gerfen and Young, 1988).   
Striatonigral and striatopallidal MSNs project from the striatum to other structures 
in the basal ganglia by two different pathways: the direct or striatonigral pathway, and the 
indirect or striatopallidal pathway.  The characterization of MSNs in the direct and 
indirect pathway accounts for striatonigral and striatopallidal MSNs in the dorsal 
striatum, and does not apply to the MSNs in the ventral striatum. Although neurons in the 
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NAcc express DRD1 and DRD2 receptors, they demonstrate different projections and 
electrophysiological properties (Smith et al., 2013; Grueter et al., 2010).   In the dorsal 
striatum, striatonigral MSNs of the direct pathway project to the globus pallidus pars 
interna (GPi) and substantia nigra pars riticulata (SNr). The striatopallidal MSNs of the 
indirect pathway project to the globus pallidus pars externa (GPe).    
Synaptic plasticity in the striatum is strongly influenced by dopaminergic 
signaling. As previously mentioned, there are two types of dopaminergic receptors 
located on striatonigral and striatopallidal neurons.  Activation of the dopamine receptors 
results in opposite physiological consequences.  Dopamine promotes motor activity by 
promoting an excitatory effect on MSNs in the direct pathway and an inhibitory effect by 
reducing activity in the indirect pathway (Fisone and Bezaard, 2011).  The different 
physiological effects occur since DRD1 and DRD2 are coupled to different G-proteins 
that exert an opposite regulatory effect on adenylyl cyclase activity.  Activation of DRD1 
results in Gαolf-mediated stimulation of adenylyl cyclase and increased production of 
cAMP, whereas DRD2 receptor binding causes Gαi/o-mediated inhibition of adenylyl 
cyclase, reducing cAMP and  protein kinase A (PKA) activity and enhancing 
phospholipase C dependent processes (Bonci and Hopf, 2005; Gerfen and Engber., 
1992).   
Striatal function maintains a balance between striatonigral and striatopallidal 
activity in order to appropriately modulate striatal input to the thalamus.  Efferent 
projections in the direct and indirect pathway provide opposite functional effects on 
thalamic excitation, which promotes normal motor and cognitive activity through 
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physiological GABAergic and glutamatergic activity.  In the direct pathway, striatonigral 
MSNs project to the GPi and upon excitation, inhibit the transient GABAergic signal 
projecting to the thalamus.  Therefore, excitation of striatonigral MSNs results in 
excitation of thalamic and thus, cortical neurons.  In the indirect pathway, striatopallidal 
MSNs inhibit GPe neurons.  Inhibition of the GPe results in disinhibition of the 
subthalamic nucleus (STN).  Projections from the STN send excitatory input to the GPi 
and SNr, which upon activation sends GABAergic inhibitory signals to the thalamus.   
Excitation of striatopallidal neurons results in the inhibition of thalamic signaling to the 
cortex.  The projections within the striatonigral and striatopallidal networks are depicted 
in fig 2 (Jenner, 2008).  Any change in the excitation of striatal neurons or in thalamic 
output results in the loss of cortical information and subsequent behavioral changes 
observed in basal ganglia disease.  
Fig 2. Changes in striatal efferent signal transmission in Parkinson’s disease and L-
Dopa induced dyskinesia.  Normal basal ganglia functioning (a) requires cortical 
glutamatergic and dopaminergic input from nigrostriatal (1) and cortical (4) neurons to 
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the striatum.  Striatonigral (3) and striatopallidal (2) neurons send GABAergic 
projections through the direct and indirect pathways.  Striatonigral neurons, through the 
direct pathway, project to the GPi, which sends GABAergic input to the thalamus.  
Striatopallidal neurons of the indirect pathways project to the GPe, which sends 
inhibitory GABAergic input to the STN.  The STN projects glutamatergic input to the 
GPi, which subsequently synapses to the thalamus.  Loss of dopamine signaling, as in 
Parkinson’s disease (b), results in an underactive direct pathway and overactive indirect 
pathway.  Subsequent L-Dopa administration (c) causes hyperactivity of the dopamine 
system that bring about opposite changes in signaling.  In LID, the direct pathway is 
overactive and the indirect pathway is underactive (figure taken from Jenner, 2008).   
 
Appropriate signal transduction in the direct and indirect pathway is required for 
sensorimotor coordination.  The classical belief about striatal contribution to the 
execution of motor functions maintains that activation of the direct pathway promotes 
desired actions, whereas activation of the indirect pathway suppresses unwanted actions 
(Nambu, 2008; Mink 2003).  Recent evidence, however, challenges the classical belief 
and suggests that co-activation of the pathways is required for proper execution of motor 
actions.  A study carried out by Cui and associates provides original evidence for co-
activation of the direct and indirect pathway during motor initiation.  Cre-dependent viral 
expression of GCaMP3 was used to monitor activity of MSNs during motor activation 
(Cui et al., 2013).  D1-Cre and A2A-Cre mice were injected with adeno-virus vectors 
containing GCaMP3in the reading frame to express GCaMP3 in the direct and indirect 
pathways of MSNs in the striatum, respectively.  TCSPC fiber optic technology was used 
to monitor fluorescence intensity of GCaMP3 to indicate calcium activity in the dorsal 
striatum.  During lever pressing operant tasks, GCaMP3 fluorescence revealed time 
locked increases at the onset of various motor actions in both direct and indirect MSNs.  
More specifically, transient signaling in both direct and indirect pathway MSNs occurred 
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within 500ms of movement initiation.  Neuronal firing in both pathways occurred during 
movement initiation, movement transition and predicted specific types of movements 
(Cui et al., 2013).  The classical inhibition/stimulation functional model predicts a higher 
frequency of transient signaling in the direct pathway during active states and a higher 
frequency of transient signaling in the indirect pathway during inactive states.  Instead, 
Cui and associates found that MSNs in both the direct and indirect pathways were firing 
during active states and depressed during inactive states (Cui et al., 2013).  The authors 
suggest that their study is in agreement with previous studies and conclusions about the 
direct and indirect pathways.  Cui and associates predict that the activation of a large 
number of MSNs in the indirect pathway would inhibit many motor actions, including 
unwanted motor actions, resulting in a hypokinetic state (Cui et al., 2013).  Conversely, 
disruption of MSNs in the indirect pathway would suppress inhibition of motor actions 
and result in a hyperkinetic state (Cui et al., 2013).  Before the classical theory is altered, 
future studies are required to provide more evidence for the individual responsibilities of 
striatonigral and striatopallidal neurons.       
 
Striatal plasticity  
The dorsal striatum displays neuronal plasticity.  Physiological excitatory input 
allows for striatal MSNs to be trained by dopamine-mediated reinforcement to recognize 
desirable voluntary behaviors (Houk and Wise, 1995) and acquire spatial knowledge 
through striatum-based learning (Reynolds and Wickens, 2002; Reynolds et al., 2001).  
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Extracellular recordings in vivo show changes in neuronal activity patterns during and 
following learning (Lauwereyns et al., 2002; Kawagoe et al., 1998). 
A burst of high frequency stimulation (HFS) enhances signal transduction and 
allows neurons to respond more efficiently to future low frequency pulses, a change in 
synaptic plasticity known as long-term potentiation LTP (Bliss and Lomo., 1973).  The 
establishment of LTP is essential to learning new information, whereas long-term 
depression (LTD) is a process that selectively weakens the synapses that have been 
strengthened by LTP.  Without LTD, LTP would not be an efficient mode of synaptic 
strengthening.  In the event that maximum synaptic strength is reached, there would be 
inhibition in the encoding of new information.  LTP and LTD were first observed in the 
striatum during in vitro studies.  Brain slice preparations with intact cortical afferents to 
the striatum exhibited both LTP and LTD when high frequency stimulation (HFS), or a 
train of pulses at 10Hz, was applied to corticostriatal fibers (Calabresi et al, 1992).  HFS 
produced different effects depending on membrane potential of the cell.  The membrane 
potential of striatal MSNs exists in two preferred states, the polarized Down-state (-94 to 
-61 mV) and the depolarized Up-state (-71 to -40 mV) (Wilson and Kawaguchi 1996).  
The Up-state maintains a membrane potential that is close to the threshold for NMDA 
receptor opening (Wilson and Kawaguchi 1996).  Therefore, it may be that high 
frequency stimulation perpetuates LTP or LTD by favoring NMDAR opening or 
glutamatergic transmission, depending on the resting membrane potential.  In vivo studies 
provided evidence that LTP and LTD are physiological mechanisms, and not a product of 
pathological circumstances (Fino et al., 2005).  In vivo studies carried out by Calabresi 
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and colleagues demonstrated that LTP proceeded with increasing NMDA activity 
(Calabresi et al., 1992).  Evidence for the presence of LTP in striatal neurons was 
established following the removal of extracellular magnesium, conditions where NMDA 
glutamate receptor activation is favored (Charpier et al., 1999; Charpier & Deniau, 1997; 
Calabresi et al., 1992).  The establishment of LTD requires selective activation of the 
mGluR1 glutamate receptor and is dependent on the influx of Ca+2 (Calabresi et al., 
1994) Depotentiation, the reversal of established LTP, also appears following the 
application of low frequency stimulation (Picconi et al., 2003).   
In the striatum, the action of normal dopamine signaling critically modulates LTP 
and LTD.  The induction of LTP is hindered in the striatum by dopamine receptor 
blockade or lesions to dopaminergic neurons projecting to the striatum (Dunnett et al., 
1992).  Modulation of LTP and LTD by dopamine signaling is essential in addition to 
proper functioning of DRD1 and DRD2 at the level of striatal MSNs, since LTP and LTD 
are abolished following genetic disruption of DARPP-32 (Calabresi et al., 2000).  
Blocking DRD1, but not DRD2, during early stages of training impairs learning of the 
task; however, with extensive training the animals eventually reach the plateau of 
learning consistent in animals with normal DRD1 signaling (Choi et al., 2005).  
 
The role of the striatum in learning and memory 
As previously mentioned, the parallel cortical loops in the cortico-basal ganglia-
thalamic circuit are responsible for cognitive and motor function.  The basal ganglia is 
involved in selecting and promoting the execution of a task.  In the same way, the basal 
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ganglia appears to be involved in learning and memory functions.  Lesion studies indicate 
that striatum-based learning can be dissociated from hippocampus based learning in the 
acquisition of spatial information (Yin and Knowlton, 2006; Packard and Knowlton, 
2002).   Insight into striatal activity has been achieved through examining neuronal 
activity while animals are learning a new task.  Many studies have found that neuronal 
firing changes during the progression of task learning (Brasted and Wise, 2004; Miyachi 
et al., 2002; Jog et al., 1999).   For example, recordings from rat striatal neurons 
demonstrate different firing patterns during early and late learning periods in the T-maze 
(Jog et al., 1999).  During early stages of training, striatal neurons fired throughout the 
different parts of the maze.  As the rat became more proficient in the task however, 
neuronal firing changed.  During the late training phase, striatal firing occurred only at 
the beginning and end of the maze.  This indicated that striatal functioning involved  first, 
execution of the task and second, reinforcement of the completion of the task by 
indicating reward evaluation and outcome (Jog et al., 1999).   
Behavioral data supports the belief that the striatum is divided into functional 
areas that correspond to neuronal projections and functional properties.  These divisions 
are important to the role the striatum plays in behavior and learning.  Goal directed 
actions and behavioral flexibility are promoted by both limbic circuit projections to the 
ventral striatum and associative cortical projections to the dorsomedial striatum (Cerovic 
et al., 2013). Projections from sensory motor cortices to the dorsolateral striatum are 
involved in motor planning and habit formation (Cerovic et al., 2013).  The dorsal 
striatum is a vital structure in motor performance and skill learning.  Learning motor 
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skills consists in the acquisition of a complex sequence of coordinated movements.  
Behavioral motor performance can be assessed using the accelerating rota-rod test, where 
an animal is placed on a rotating rod that accelerates gradually requiring the animal to 
learn to coordinate their movements and keep balance in order to avoid falling from the 
rod.  A 3-day training protocol for the rota-rod test was executed and found to elicit 
increased phosphorylation levels of extracellular signal-regulated protein kinase 1 and 2 
(ERK) in the dorsal striatum once learning was consolidated by day 3, but not on day 1 of 
training (Bureau et al., 2010).  Intrastriatal injection of MEK inhibitor PD98059 into the 
dorsal striatum impaired the improvement of motor coordination and balance, however 
without altering initial motor performance.  ERK activation in the dorsal striatum aided in 
the consolidation of motor skill performance, following 3 days of training in the rota-rod 
task (Bureau et al., 2010), suggesting that striatal function supports sensorimotor skill 
building.   
    The role of the striatum in spatial and place learning has been assessed in the 
Morris water maze (Vorhees and Williams, 2006). Early studies demonstrate that lesions 
of the medial striatum impair swim latencies in both the place and cue acquisition 
(Whishaw et al., 1987). Lesions of the lateral striatum were shown to impair cue learning 
in the water maze (McDonald and White, 1994). The dissociation between medial and 
lateral striatum on the cue and place learning were also shown (Devan et al., 1999).  
Specifically, it was observed that dorsomedial lesions led to impairment in place and cue 
learning, and preferential responses to local cues (Devan et al., 1999).  A recent study 
demonstrated that functioning of the dorsomedial striatum is correlated with the initial 
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acquisition of place learning in the water maze (Woolley et al., 2013).  It was observed 
that both the dorsomedial striatum and medial prefrontal cortex support early stages in 
the acquisition of spatial learning, in both human and mouse.  This suggests that the 
cortical-basal ganglia- thalamic circuit involving the medial prefrontal cortex and 
dorsomedial striatum supports early learning stages, and that the dorsolateral and 
dorsomedial striatum play different roles in spatial learning(Woolley et al., 2013).  It is 
likely that striatum-based learning and memory involves the activation of GABAergic 
neurons. In particular, it is possible that modulation of GABAergic neurotransmission in 
the striatum is involved in place and cue-learning in a water maze.  
 
Parkinson’s disease: a basal ganglia disorder 
Dysfunction in dopaminergic signaling leads to many pathological conditions like 
Parkinson’s disease (PD), a common neurodegenerative basal ganglia disease that results 
from the loss of dopaminergic neurons in the SNc (Ehringer and Hornykiewicz, 1960).  
The striatum is a major contributor to PD, as it is a major recipient of basal ganglia 
dopaminergic input.  The progressive degeneration of neurons in the SNc results in loss 
of the nigrostriatal pathway and the symptoms that characterize PD, such as tremor, 
bradykinesia, postural abnormalities and rigidity (Fahn, 2003).  These symptoms are 
attributed to an imbalance in striatonigral and striatopallidal output to the thalamus.   
Changes in striatal efferent processing caused by dopaminergic denervation  
In PD, dopaminergic denervation of SNc neurons accounts for the progressive 
immobility that is characteristic of the disease.  Progressive immobility is potentiated by 
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continued depression of direct and indirect pathway activity, reducing input to the 
thalamus (fig 2; Jenner, 2008).  Normally, nigrostriatal projections release dopamine and 
exert an inhibitory effect on striatopallidal MSNs.  Decreased activation of the indirect 
pathway however, enhances GABAergic output from striatopallidal MSNs to the GPe.  
Inhibition of the GPe results in decreased GABAergic input to the STN, causing the STN 
to generate higher than normal activation of the GPi.  The GPi projects GABAergic 
signaling to the thalamus.  When the GPi is over active, as in PD, the thalamus becomes 
further inhibited and sends less excitatory input to the cortex.  Striatonigral neurons also 
exhibit decreased excitatory output following the denervation of nigrostriatal projection 
neurons.  Decreased activity in the direct pathway results in decreased GABAergic output 
from the GPi and increased inhibition of the thalamus (fig 2; Jenner, 2008).  The 
cumulative depression of the direct and indirect pathway by dopaminergic denervation of 
the SNc causes decreased thalamic signaling to the cortex and impairs motor activity.    
L-Dopa induced dyskinesia  
The symptoms of PD are traditionally treated with Levodopa (L-Dopa), a 
metabolic precursor to dopamine.  Treatment with L-Dopa and dopamine receptor 
agonists effectively reverses symptoms of tremor, rigidity and hypokinesia in the early 
stages of PD.  If introduction of L-Dopa occurs during the early stages of PD, L-Dopa 
provides adequate artificial means of dopamine for storage in presynaptic dopamine 
terminals and continuous, normal release of dopamine (Goto et al., 2007; Grace, 1995).  
However, progressive denervation of dopaminergic neurons in the SNc leads to pulsatile 
dopamine release that alters basal ganglia output (Obeso et al., 2004).  As a result, long-
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term use of pharmacological dopamine replacement often results in decreased therapeutic 
effectiveness and dyskinesia, or abnormal involuntary movements, including dystonic 
and choric movements (Obeso et al., 2000).  Although L-Dopa remains the most effective 
therapeutic approach to treating PD, the development of dyskinesia through the use of L-
Dopa often leads to the development of L-Dopa induced dyskinesia (LID) (Cotzias et al., 
1969; Mercuri and Bernardi, 2005).  Several factors are believed to contribute to LID 
such as the onset of PD, duration of PD and high dosage of L-Dopa during the chronic 
development of PD (Fisone and Bezard, 2011).   
It is generally believed that the effects of L-Dopa on MSNs in the striatum 
contrast the signaling imbalance in the striatonigral and striatopallidal pathways observed 
in PD.  The effect of L-Dopa on the direct and indirect pathway is depicted in fig 2 
(Jenner, 2008).  Introduction of L-Dopa directly increases DRD1 and DRD2 receptor 
activity, which results in an overactive thalamus, increased excitability in the motor 
cortex and erratic involuntary movements (Jenner, 2008).  Upon the induction of LID, 
every administration of L-Dopa, or pharmacological dopaminergic agonists, thereafter 
results in abnormal involuntary movements (Jenner, 2008).  The development of 
dyskinesia poses the most problematic obstacle in the treatment of PD.  Therefore, there 
is a need to understand the mechanisms contributing to LID in order to propose more 
suitable treatments for PD.   
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Molecular contributions to LID 
Evidence suggests that the induction of LID may result from the abnormal 
fluctuation of dopamine levels derived from L-Dopa.  The use of L-Dopa, concurrently 
with the progression of PD, leads to a non-physiological stimulation of dopamine 
receptors and dopaminergic signal transduction in striatal efferent neurons (Jenner, 2008; 
Fisone and Bezard, 2011).  This occurs due to the pharmacological profile of L-Dopa, 
and dopaminergic agonists; and the conversion of L-Dopa to dopamine in other neuronal 
or non-neuronal cell types (Jenner, 2008).  Animal models with unilateral 6-
hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
lesions are treated with L-Dopa or dopamine agonists to mimic the onset of LID in order 
to examine the mechanisms contributing to symptomatology and molecular mechanisms 
of LID.  Moreover, non-physiological dopamine release contributes to the presynaptic 
irregularities and efferent signal transduction abnormalities in GABAergic MSNs of the 
striatum (Fisone and Bezard, 2011; Jenner et al., 2008).   
Presynaptic changes  
When L-Dopa is used to treat patients in the early stages of PD, it is believed that 
L-Dopa is taken up in spared dopaminergic neurons and terminals, where it is converted 
to dopamine and released physiologically (Cenci, 2006).  With the progression of PD, 
fewer dopamine terminals convert L-Dopa to dopamine and the release of dopamine 
becomes less physiological.  As this occurs, L-Dopa is converted in other neuronal and 
non-neuronal cells.  Serotonin neurons express amino acid decarboxylase (AADC) and 
vesicular monoamine transporter 2 (VMAT2), which have been shown to convert L-Dopa 
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to dopamine and store dopamine in the synaptic vesicles (Arai et al., 1995).  In a recent 
study, serotonin neuron transplants to the striatum were shown to increase symptoms 
observed in dyskinesia following L-Dopa treatment (Carlsson et al., 2007).   Removal of 
serotonin innervation by injection of 5,7-DHT or pharmacological silencing with 5-HTIA 
and 5-HTIB receptor agonists resulted in attenuation of both LID and the enhanced 
release of dopamine in the striatum in 6-OHDA lesioned rats (Lindgren et al., 2010; Carta 
et al., 2007; Kannari et al., 2001).  Sprouting of serotonin axon terminals in the striatum 
has also been demonstrated following L-Dopa treatment (Rylander et al., 2010).  
  Aberrant signal transduction in striatonigral neurons  
The loss of dopamine in SNc neurons results in increased expression and 
responsiveness to dopaminergic drugs in the striatonigral pathway, which is thought to 
occur as a compensatory mechanism due to the lack of dopamine present.  Studies have 
shown that denervation of nigrostriatal neurons and chronic L-Dopa treatment results in 
increased expression of DRD1 (Berthet et al., 2009; Guigoni et al., 2007).  However, the 
change in dopaminergic sensitivity is not believed to occur due to increases in number or 
affinity in striatal DRD1 receptors, as neither 6-OHDA or MPTP lesioned animals 
(Aubert et al., 2005)  nor Parkinson’s patients show this trend (Hurley et al., 2001).  
Instead, striatonigral MSNs may become more responsive to dopamine due to increased 
levels of Gαolf (Rangel-Barajas et al., 2011; Corvol et al., 2004) and Gαolf-D1R 
coupling (Aubert et al., 2005).  In one study, Aubert and colleagues showed that the 
severity of LID was correlated with a normalized increase in DRD1 agonist induced 
[35S]GTPγs binding in the striatum indicating increased D1R- Gαolf coupling.  Dopamine 
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denervation by unilateral injection of MPTP and subsequent L-Dopa treatment caused 
differential effects on [35S]GTPγs binding.  MPTP treatment alone caused a decrease in 
[35S]GTPγs binding.  Subsequent L-Dopa treatment induced a different effect in 
dyskinetic and nondyskinetic animals.  In animals that did not develop dyskinesia, L-
Dopa treatment caused [35S]GTPγs binding to return to control level.  However, a steep 
increase in [35S]GTPγs binding occurred in animals that developed dyskinesia (Aubert et 
al., 2005).   
The cAMP response element (CREB) pathway is involved in regulating neural 
plasticity and learning (Jancic et al., 2009).  Dysregulation of neural signaling in 
striatonigral MSNs of the dorsomedial striatum, results in changes involving cAMP 
mediated neural plasticity, which affects behavioral outcomes (Ferguson et al., 2013).  
Striatonigral neurons have been observed to exhibit cAMP dependent changes in 
dyskinesia (Santini et al., 2009; Rangel-Barajas et al., 2008).  The increase in cAMP has 
been shown to occur due to DRD1 sensitivity.  Rangel-Barajas and colleagues, observed 
an increase in adenylyl cyclase type V in the striatum and SNr in 6-OHDA lesioned rats 
treated with L-Dopa (Rangel-Barajas et al., 2011).  Enhanced adenylyl cyclase type V 
expression was pronounced only in dyskinetic animals (Rangel-Barajas et al., 2011).  The 
compensatory increase in DRD1-mediated production of cAMP, caused by the over-
expression of Gαolf and adenylyl cyclase type V provides evidence for increased 
sensitivity of DRD1 in striatonigral MSNs of the direct pathway in LID.  The hypothesis 
has been further supported on the basis that the infusion of Rp-cAMPS, a cAMP-
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dependent protein kinase (PKA) inhibitor has been shown to attenuate LID (Lebel et al., 
2010).   
Increased activity of molecular and cellular mechanisms in striatonigral neurons 
have been shown to enhance GABAergic signaling in the direct pathway (Rangel-Barajas 
et al., 2011, 2008; Yamamoto et al., 2006).  Rangel-Barajas and co-workers showed that 
depolarization of DRD1 on striatonigral MSNs induced [3H]-GABA release in the SNr 
following denervation and L-Dopa treatment (Rangel-Barajas et al., 2008).  They further 
discovered that an increase in adenylyl cyclase activity was responsible for the enhanced 
GABA release that contributes to dyskinesia.  Experiments revealed that adenylyl cyclase 
type V/VI expression was elevated following a unilateral 6-OHDA lesion and was further 
enhanced by L-Dopa treatment in rats with severe dyskinesia (Rangel-Barajas et al., 
2011).  The levels of adenylyl cyclase expression and [3H]-GABA release paralleled the 
severity of dyskinetic effects of L-Dopa.   Levels of Gαolf expression were increased 
following dopaminergic denervation, but normalized upon L-Dopa administration.  Basal 
cAMP production was not affected by the 6-OHDA lesion or subsequent L-Dopa 
treatment however, activation of DRD1 receptors by SKF81297DRD1 agonist, greatly 
increased cAMP production.  The link between cAMP production and GABA release was 
demonstrated by using NKY80, an inhibitor of adenylyl cyclase type V/VI.  Parallel 
effects on [3H]-GABA and cAMP production were observed and thus suggest that cAMP 
production and GABA release occur by the same mechanism (Rangel-Barajas et al, 
2011).  These conclusions are supported by studies that show [3H]-GABA release by 
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activation of DRD1 in the striatum and SNr is mediated by increased adenylyl cyclase 
activity (Arias Montano 2007, Nava Asbell 2007).  
It is believed that aberrant movements seen in dyskinesia are further exacerbated 
by increased AMPA and NMDA glutamatergic transmission.  A target of PKA 
phosphorylation in MSNs is the 32 kDa dopamine and cAMP regulated phosphoprotein 
(DARPP-32), which plays an important role in DRD1 mediated transmission in the 
striatum (Greengard, 2001).  L-Dopa treated dopamine deficient animals show increased 
DARPP-32 phosphorylation, which persists only in animals that develop dyskinesia 
(Lebel et al., 2010; Santini et al., 2010, 2007).  Cell specific inactivation of DARPP-32 
occurs in MSNs of the direct pathway, but not in the indirect pathway (Bateup et al., 
2010).  Knocking out DARPP-32 results in the attenuation of LID (Santini et al., 2007).  
DARPP-32 has been associated with phosphorylation of the GluR1, a subunit of the 
AMPA glutamate receptor, which promotes excitatory glutamatergic transmission 
(Mangiavacchi and Wolf, 2004; Banke et al., 2000).  Additional recruitment of AMPA 
receptor subunits, GluR2 and GluR3 have also been found in dyskinetic primates 
(Silverdale et al., 2010).  Enhanced and reduced severity of LID has been observed with 
AMPA receptor agonists and antagonists, respectively (Konitsiotis et al., 2000). 
 Increased activation of ERK has been shown to exacerbate dyskinesia, whereas 
inhibition of ERK attenuates dyskinesia.   In the striatum, ERK is regulated by activation 
of DRD1 and NMDA receptors (Valjent et al., 2005).  L-Dopa has been found to activate 
ERK in dopamine deficient animals (Santini et al, 2007).  The activation of ERK depends 
on DARPP-32 phosphorylation.  This is consistent in animals that develop dyskinesia and 
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demonstrate elevated levels of DARP-32 phosphorylated ERK (Gerfen et al., 2008).  In 
mouse, LID has been associated with the promotion of ERK signaling due to the changes 
in expression of calcium and diacylglycerol-guanine exchange factors (CalDAG-GEF) I 
and II, which regulate the G-protein activity via Ras GTPases in MSNs in the striatum 
(Crittenden et al., 2009).  It was observed that the severity of dyskinesia correlates with 
increased CalDAG-GEFII and decreased CalDAG-GEFI expression in the striatum 
(Crittenden et al., 2009).  The inhibition of ERK phosphorylation has been shown to 
reduce the severity of LID in several studies.  These studies describe the importance of 
ERK phosphorylation in LID (Schuster et al., 2008; Santini et al., 2007).  Interestingly, 
genetic inactivation of Ras-guanyl nucleotide releasing factor I (Ras-GRF1), a brain 
specific activator of the ERK cascade also attenuates dyskinesia in mice and primates 
(Fasano et al., 2010).   
There is increased expression and density of NMDA receptors in the post synaptic 
cleft following activation of DRD1 in striatonigral MSNs (Hallett et al., 2006).   
Additionally, there is a reduction in NMDA receptor inactivation due to the 
downregulation of the DRD1-NMDA complex in animals that develop dyskinesia 
(Fiorentini et al., 2006).  Without this complex, NMDA transmission is enhanced because 
the DRD1-NMDA complex is no longer functioning to desensitize NMDA receptor 
transmission.  The metabotropic glutamate receptor 5 (mGluR5) is expressed in striatal 
MSNs, where it potentiates NMDA excitatory synaptic transmission (Kumar et al., 2008).  
Upon L-Dopa treatment, there is an increase in mGluR5 binding in dyskinetic animals.  
Antagonists of mGluR5 reduce LID (Yamamoto and Soghomonian 2009); therefore, 
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blocking mGluR5 may be counteracting increases in NMDA receptor transmission seen 
in LID. 
Modifications in striatopallidal efferent signaling  
Inhibitory signaling in the indirect pathway decreases following dopaminergic 
denervation.  L-Dopa does not restore inhibitory signaling, but instead contributes to 
aberrant signaling patterns caused by the presynaptic changes that occur in LID.  
Substantial evidence supports the involvement of the direct pathway in LID induction and 
maintenance however, little is known about the contribution of MSNs of the indirect 
pathway.   
Studies show that morphology and signal transduction changes in striatopallidal 
MSNs accompany dyskinesia.   Changes in Cav1.3 L-type Ca+2 channel regulation 
results in loss of dendritic spines and glutamatergic synapses in striatopallidal neurons in 
the indirect pathway following nigrostriatal denervation (Day et al., 2006).  
Administration of isradipine, a Ca 1.2-1.3 L-type Ca+2 channel antagonist, reduces 
rotation symptoms observed in LID and prevents spine loss (Schuster et al., 2009).  
Therefore, the decreased number of spines and dendritic connections is likely to alter 
striatal signaling in striatopallidal projection neurons and contribute to dyskinesia.      
Restoring physiological signaling in the indirect pathway may attenuate 
dyskinesia.  Striatopallidal neurons express the adenosine binding A2A type receptor 
(Fink et al., 1992).  Activation of the A2A receptor opposes inhibitory signaling, a 
hallmark of striatopallidal projection neurons (Stoff and Kebabian, 1981), by facilitating 
stimulation of adenylyl cyclase and cAMP production (Corvol et al., 2001).   A2A 
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receptor antagonists prevent dyskinesia induced by apomorphine, a dopamine agonist 
(Bibbiani et al., 2003).  Therapeutic effects of A2A antagonists may relieve symptoms of 
dyskinesia by promoting the function of the indirect pathway.  However, A2A receptors 
are also located on corticostriatal terminals and promote glutamate release (Quiroz et al., 
2009).  Therefore, A2A receptors may contribute to mechanisms of LID through the 
action of glutamatergic signaling and not striatopallidal signaling.  While it may seem 
unclear how the indirect pathway contributes to LID, there is direct evidence that 
enhanced signal transduction in striatopallidal neurons perpetuates dyskinesia.  Increased 
expression of regulatory GPCR signaling protein 9-2 (RGS9-2), a striatal GTPase 
accelerating protein (Rahman et al., 1999) that reduces DRD2 mediated transmission, 
attenuates dyskinesia (Gold et al., 2007).  Down regulation of RGS9-2 in knockout mice 
enhances the severity of LID (Gold et al., 2007).  However, increased RGS9-2 by viral 
vector potentiation attenuates dyskinetic symptoms in dopamine depleted primates 
treated with L-Dopa and maintains the therapeutic effects of L-Dopa (Gold et al., 2007).   
Abolishing the excessive inhibition of the indirect pathway seems to have therapeutic 
effects for dyskinesia.  
 
Glutamic acid decarboxylase  
γ-Aminobutyric acid (GABA) is the principal inhibitory neurotransmitter of the 
central nervous system and is found in efferent MSNs in the striatonigral and 
striatopallidal pathways, as well as in some medium and large aspiny interneurons 
(Bolam et al., 1985).  GABA is synthetized from glutamate via the rate limiting enzyme 
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glutamic acid decarboxylase (GAD).  There are two isoforms of GAD, GAD 67 and 
GAD 65, which are encoded by the genes Gad 1 and Gad 2, respectively (Erlander and 
Tobin, 1991).  Both GAD isoforms are co-expressed in most GABAergic neurons 
(Esclapez et al., 1994).   
GAD immunoreactivity reveals that Gad65 is mostly found in nerve terminals, 
while GAD67 is found in both neuronal cell bodies and nerve terminals (Erlander et al., 
1991).  The Gad65 and Gad67 isoforms provide a dual system for GABA synthesis.  Gad 
67 is thought to catalyze GABA under physiological resting conditions, whereas Gad65 
primarily produces activity dependent GABA (Soghomonian and Martin, 1998).  
Evidence for this is supported by GABA levels found in genetically modified GAD67 
and GAD65 knockout mice.  GAD65 knockout mice show normal levels of GAD67 and 
brain GABA levels (Asada, 1996).  In addition, spontaneous IPSCs amplitudes remain 
stable in mice lacking Gad65 (Tian et al., 1999).  However, total GABA levels are 
reduced in heterozygous GAD67 knockout mice (Asada et al., 1997).  Where brain 
GABA levels are enhanced with vigabatrin, an inhibitor of GABA-T, the synthesis of 
cortical GABA decreases 70% (Sheikh and Martin, 1998).  Introduction of vigabatrin 
results in a significant reduction of GAD67 expression throughout the brain and a slight 
decrease in the expression of GAD65 only in the cerebellum (Sheikh and Martin, 1998).   
It has also been demonstrated that Gad67 contributes to 90% of neuronal GABA 
synthesis (Asada et al., 1997).  In a more recent study, Lau and Murthy describe the role 
of GAD67 in basal GABA synthesis and vesicular filling in in vivo and in vitro studies.  
It was observed that the deletion of GAD1 by the genomic insertion of GFP invariably 
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reduced miniature inhibitory post synaptic current (mIPSC) amplitude, GABA levels, and 
GABA vesicular filling in hippocampal neuron cultures.  Application of tetrodotoxin, 
which dampened neuronal activity, further reduced mIPSC amplitude, GABA levels and 
Gad67 expression; whereas picrotoxin, an enhancer of neuronal activity, amplified 
GABA levels and increased Gad67 expression.  This study demonstrates that Gad67 is a 
major target of activity dependent regulation of cytosolic and vesicular GABA 
concentration (Lau and Murthy, 2012).   Furthermore, it seems that GAD65 does not 
compensate for the GABA produced by GAD67 and that GAD67 can support normal 
GABAergic signaling.   
As of late, the expression of GAD1 and GAD2 has been more closely examined in 
the striatum.  Gad1 expression was observed primarily in MSNs located in the lateral 
striatal streak in transgenic Cb6-Tg (Gad1-EGFP)G42ZZjh/J transgenic mice where the 
GAD1 promoter drives GFP expression (Cuzon Carlson et al., 2011).  Additional 
experiments were carried out by Trifonov and colleagues, who examined the distribution 
and intensity of GAD1 and Gad2 mRNA in MSNs with different striatal markers in the 
mouse and rat brain.  Hybridization and immunohistological studies revealed high levels 
of Gad1 expression within the lateral striatum, but not of Gad2 (Trifonov et al., 2012).  In 
the striatum, medium spiny projection neurons revealed both Gad1 and Gad2 labeling.  
Most striatal neurons were labeled with both Gad1 and Gad2 probes however, a 
subpopulation of neurons in the lateral striatum were only labeled for Gad1 mRNA.  The 
lateral regions of the striatum were labeled more intensely for Gad1 mRNA than any 
other part of the striatum and yielded identical Gad1 expression patterns with the three 
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different probes.  It was further confirmed that GAD67 exhibited higher expression in the 
lateral striatum than in the medial striatum (Trifonov et al., 2012).  Although GAD1 
mRNA is thought to be expressed in both subtypes of striatal projection neurons, a 
double label study is required to investigate the distribution of GAD1 in striatonigral and 
striatopallidal neurons. 
Dopaminergic influence on GAD mRNA expression and GABA release  
Dopamine terminals innervate striatal GABAergic neurons; therefore, there is a 
physiological basis for the direct influence of dopamine on striatal signaling.  Prior 
studies have demonstrated that there is a direct dopaminergic influence on GAD65 and 
GAD67 expression.  Increased and decreased dopamine transmission produced opposite 
effects on GAD67 expression (Linderfors, 1993).  Experiments utilizing a unilateral 6-
OHDA or MPTP lesion demonstrate that the loss of nigrostriatal dopamine neurons 
results in increased GAD67 mRNA levels, but not GAD65, by Northern blot analysis and 
in situ hybridization (Lindefors et al., 1989; Soghomonian and Chesselet 1992).  The 
changes in Gad67 mRNA levels occur ipsilateral to the site of the lesion in the 
dorsolateral and ventromedial striatum (Katz et al., 2005; Perier et al., 2003).  Increase in 
striatal GAD enzymatic activity parallels the increase in GAD67 mRNA levels, as 
demonstrated one and four months following dopaminergic denervation (Segovia et al., 
1990).   There is also an increase in GABA production and extracellular release 
(Linderfors et al., 1989).   
Studies have shown that administration of L-Dopa to 6-OHDA lesioned rats 
results in a further increases of GAD67 mRNA levels (Horvath et al., 2011; Bacci et al., 
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2002) in both striatonigral and striatopallidal neurons (Carta et al., 2003).  The additional 
increase in GAD67 mRNA primarily occurs in striatonigral neurons and to a lesser 
extent, striatopallidal neurons (Frau et al., 2013; Yamamoto et al., 2009; Nielsen et al., 
2004; Cenci et al., 1998) and is dose dependent (Katz et al., 2005).  Chronic 
administration of L-Dopa to 6-OHDA lesioned rodents results in increased levels of 
GAD67 expression in the globus pallidus (GP), (Carta et al., 2003) and GABA release in 
the SNr (Rangel-Barajas et al, 2011, 2008; Yamamoto et al., 2006).  The severity of LID 
has also been shown to parallel the increase in Gad67 following administration of L-
Dopa in dyskinetic animal models (Cenci et al., 1998) progressively with the number of 
L-Dopa injections (Katz et al., 2005).  Although administration of L-Dopa can also cause 
an increase in Gad65, only Gad67 expression is altered with the administration of L-Dopa 
in dopamine deficient animals (Katz et al., 2005; Laprade et al., 1999).  Increased Gad67 
and Gad65 expression occurs in a time dependent manner, such that Gad67 is increased 
at 72 hours but not at 3 hours and Gad65 is increased at 3 hours following a single 
injection of D1/D5 receptor agonist SKF-81297 to dopamine depleted rats (Yamamoto 
and Soghomonian, 2008).  Vesicular GABA transporter (v-GAT) is also increased in the 
striatum, but occurs between 72 hours and 3 days following chronic daily injection of the 
dopamine receptor agonist.  Moreover, striatal levels of Gad67 mRNA are negatively 
correlated with nigral levels of the GABAA α1 receptor subunit, which are thought to 
decrease as a compensatory mechanism for the increase in striatal Gad67 and Gad65 
expression following dopamine receptor agonist administration (Yamamoto and 
Soghomonian, 2008). The increase in GAD67, as observed with dopamine depletion and 
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L-Dopa treatment can be reversed with glutamate metabotropic mGluR5 antagonist 
(MPEP) co-administration with L-Dopa (Yamamoto and Soghomonian, 2009).  
Administering MPEP with L-Dopa attenuates dyskinesia, and suggests that the 
compensatory changes observed in LID following the upreguation of Gad67 may be 
reversed by downregulating Gad67 in the striatum. 
 
Objective  
The general objective in this thesis is to examine the role of Gad1 and Gad67 in 
striatal neurons on GABAergic neurotransmission and on behavior in intact mice and in 
dopamine-depleted mice.  There is significant complexity in basal ganglia function due to 
the integration of parallel networks within the cortical-basal ganglia-thalamic circuit that 
account for motor, cognitive and emotional tasks.  The striatum is the major input 
structure of the basal ganglia and is essential to normal basal ganglia function.  Around 
95% of all neurons in the striatum use GABA as a neurotransmitter (Kreitzer, 2009) 
therefore, striatal function is likely to be defined by the activation of GABAergic 
signaling to external basal ganglia regions.  Lesion studies have begun to examine the 
role of striatal function.   However, the contribution of GABAergic signaling in the 
striatum to normal and disease basal ganglia function has not been thoroughly explored.  
Gad67 has been shown to account for 90% of neural GABA synthesis (Asada et al., 
1997).  A deletion in Gad1 in Gad1-/- knockout mice results in reduced GABA 
expression, mIPSC amplitude and vesicular filling of GABA at post-synaptic terminals 
(Lau and Murthy, 2012).   
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To investigate the role of striatal GABAergic signaling, Gad67 was deleted in 
Gpr88 expressing neurons.  Gpr88 is a G-protein receptor that is highly expressed in 
striatal MSNs (Quintana et al., 2012; Massart et al., 2009).  In this study, Gad67 is 
deleted by Cre-mediated recombination in conditional knockout mice.  In conditional 
knockout mice, the open reading frame of GPR88 was replaced with a cassette encoding 
Cre recombinase-GFP fusion protein (Gpr88Cre-GFP), which is under the control of the 
Gpr88 promoter (Quintana et al., 2012).  In addition, exon 2 of Gad1 is flanked by lox P 
sites in the conditional knockout mice.  When Gpr88 containing neurons express 
Gpr88Cre-GFP, Cre-mediated excision of Gad67 occurs.  
Two different experiments were carried out to explore the contribution of normal 
striatal GABA signaling in intact and dyskinetic mice.  First, the molecular and 
behavioral effects of deleting Gad1 in Gpr88 containing neurons were determined in 
conditional knockout mice.  This was accomplished by immunohistochemical analysis of 
Gad67 and GFP reporter expression, and electrophysiological studies investigating 
spontaneous IPSCs of striatal MSNs.  Behavioral analysis of mice with a deletion in 
Gad67 included assessment of motor coordination, learning and memory.  Next, the 
contribution of Gad67 catalyzed GABAergic activity to LID was explored in L-Dopa 
treated, 6-OHDA lesioned conditional knockout mice.  Gad67 is increased following L-
Dopa and dopamine receptor agonist administration to dopamine deficient animals 
therefore, it may be possible that a deletion in striatal Gad67 will decrease dyskinesia.  In 
addition, motor performance and forelimb asymmetry was investigated to assess whether 
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Gad67 affects deficits in motor coordination observed in dopamine deficient and 
dyskinetic animals.       
This study had two major objectives.  The first was to characterize 
Gpr88CreGFP::Gad1lox/Δ conditional knockout mice using immunohistochemistry, 
genotyping, electrophysiology and behavioral analysis.  The second goal was to examine 
the role of Gad67 in the striatum in L-Dopa induced dyskinesia (LID) and other motor 
impairments induced by a unilateral loss of dopamine neurons in control and conditional 
knockout mice.  The following specific objectives were reached: 
(1) PCR genotyping confirmation that we bred Gpr88CreGFP:Gad1lox/Δ  conditional 
knockout and Gpr88+/+::Gad1lox/Δ control mouse lines 
(2) Evidence for a differential expression of Gpr88 and Gad67 in conditional 
knockout and control mice 
(3) Electrophysiological evidence that conditional knockout mice have decreased 
frequency of spontaneous IPSCs in striatal MSNs  
(4) Demonstrating that striatal Gad1 deletion impairs learning in the Morris 
water maze but not motor performance using the rota-rod  test 
(5) Demonstrating that loss of Gad1 in striatal neurons does not improve the 
severity of L-Dopa induced dyskinesia in conditional knockout mice with a 
unilateral lesion of dopamine neurons  
(6) Demonstrating that loss of Gad1 alters motor and forelimb asymmetry deficits 
induced by L-Dopa in mice with a unilateral lesion of dopamine neurons  
 
 34 
METHODS 
 
Animals 
Mice were housed in an animal facility and subject to 12 hour light and dark 
cycles. Food and water were available ad libitum. All mice were tested between 2 and 6 
months of age. The mouse lines used in these experiments were backcrossed to C57BL/6 
mice. Animal protocols and procedures were approved by Boston University School of 
Medicine Institutional Animal Care and Use Committee.  
 
Generation of conditional knockout and control mice 
Two genetically modified mice lines, Gpr88CreGFP::Gad1 Δ /+ and Gad1lox/lox, were 
crossed to generate Gpr88CreGFP::Gad1 Δ /lox and Gpr88+/+::Gad1 Δ /lox mice.  Of the 
resulting progeny, Gpr88CreGFP/+::Gad1 Δ /lox mice are designated as the conditional 
knockout mice and Gpr88+/+::Gad1 Δ /lox mice are designated as the control.  Mouse lines 
were provided by Dr. Richard Palmiter (U. Washington).  Gad1lox/+ mice were bred with 
each other to generate Gad1lox/lox mice or with Mox2Cre mice (Tallquist and Soriano, 
2000) to delete Gad1 exon 2 in the germline (Gad1Δ /+).  In Gad1lox/lox mice, exon 2 of the 
Gad1 gene was flanked by loxP sites (floxed Gad1) (fig 3b) (Heusner et al., 2008).  In the 
second mouse line, Cre-GFP was targeted to the first coding exon of the Gpr88 locus, 
rendering Gpr88Cre under the control of the Gpr88 promoter (fig 3a) (Quintana et al., 
2012).  To produce Gpr88CreGFP::Gad1Δ /+ mice, Gad1Δ/+ mice were bred with 
Gpr88CreGFP mice.  In Gpr88CreGFP mice, gene targeting methods were used to replace the 
open reading frame of Gpr88 with a cassette encoding the Cre-recombinase-GFP fusion 
 35 
protein (Gpr88-CreGFP) (fig 3a) (Quintana et al., 2012).  Replacement of the Gpr88 
allele with the modified protein construct rendered Cre-recombinase expression under the 
control of the Gpr88 promoter.  Gpr88Cre/Cre mice were previously shown to exhibit 
enhanced excitability of MSNs and deficits in motor performance and learning (Quintana 
et al., 2012).  Cre recombinase acts to carry out site specific recombination of DNA 
flanked by loxP sites thus, removing the mRNA prior to translation.  In conditional 
knockout mice used in this study, Cre-mediated recombination excises exon2 of the Gad1 
gene, rendering it inactive.  Gad1 codes for Gad67, which catalyzes the production of 
GABA from glutamic acid in the brain (Asada et al., 1997).   Therefore, Gad67 is deleted 
in all cells expressing Gpr88Cre-GFP.  Control mice however, do no express Gpr88-
CreGFP, but do express the floxed Gad1 allele therefore, neurons containing the floxed 
Gad1 allele cannot undergo Cre-mediated recombination and Gad67 is not deleted.  
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Fig 3. Generation of Gpr88CreGFP::Gad1lox/ conditional knockout mice.   Targeting 
strategy for the generation of Gpr88-CreGFP mice (A)  Targeting strategy for the 
generation of Gad1 floxed mice (B).  The endogenous Gad1 locus (top) and targeting 
vector containing loxP sites (ovals) (bottom) are represented.  (Figure A taken from 
Quintana et al., 2012; Figure B taken from Heusner et al., 2008) 
 
PCR Genotyping  
DNA was amplified by PCR to determine mouse genotype.  Primers for Gad1 and 
Gpr88frt (Quintana et al., 2012) were designed from published sequences.  The following 
primers were used: for the GAD1 gene, forward primer (5’-GCT ACT GTG CTT GCG 
CCC CAG TC-3’) and reverse primer 5’-GTA ACC TCG CGT CCC TGG CAG CC-3’) 
and for the Gpr88Cre  gene, forward primer (5’-TGG AGG AAC GAG GAG TTC CGC -
3’) and reverse primer (5’-AGA AGG AGG CAG TGC GGC AGG -3’).  DNA was 
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isolated from 2 mm of mouse tail.  To break down cells and proteins, 100μL of extraction 
buffer and 1% 2-Marcaptoethanol (Fisher Scientific, Hampton, NH) were added to the 
mouse tail and heated at 95°C for 10 min.  Next, 3μL Protein Kinase K was added and 
the tissue was heated at 55°C for 1 hour, vortexed, and transferred to 95°C for an 
additional 10 min.  DNA was amplified by PCR using BioRad/MJ PTC 200 Gradient 
Thermocycler.   The PCR reaction was assembled by the addition of 5 μL red solution 
(Sigma Aldrich, St. Louis, MO), 5μM forward and reverse primers, and 2 μL extracted 
DNA in a final volume of 10μL.  PCR cycling programs were carried out according to 
manufactures instructions (Millipore, Billerica, MA).  To analyze the PCR products, a 
3% agarose gel with 1X TBE buffer was prepared and loaded with samples.  
 
Experimental Design for the Behavioral Analyses 
Two different behavioral experiments were comprised in this study.  First, 
conditional knockout mice were characterized by behavioral tests including the Morris 
Water Maze and the Rota-rod test (N=14, conditional knockout n=8 control=6).  Next, 
behavioral testing was used to evaluate the role of striatal Gad67 in LID.  Again, there 
were two experimental groups comprised in this study, (N=5 conditional knockout n=3 
and control n=2).  Both groups were subject to a unilateral 6-OHDA lesion, L-Dopa 
treatment and testing conditions.  The time line of the implemented procedures and 
behavioral testing for the second experiment is depicted in fig 4.  Behavioral testing was 
performed in intact mice, 6-OHDA lesioned mice and subsequently L-Dopa treated mice.  
Additional prior testing was carried for the second experiment.  Results from prior 
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experiments were combined to represent the overall effects of L-DOPA in conditional 
knockout mice.  Prior behavioral tests included AIMs (N=14 conditional knockout n=8 
control n=6) and the pole test (N=13 conditional knockout n=7 and control n=6).  The 
results of AIMs and the pole test represent the pooled sample. 
 
 
Fig 4. Experimental design for LID experiment.  The schematic outlines the time 
course for the LID experiment.  All mice (N = 5; conditional knockout n = 2, control n = 
3) received unilateral 6-OHDA lesions.  Mice were tested for motor coordination and 
balance, forelimb preference both prior to 6-OHDA lesioning (week 1), following the 6-
OHDA lesion recovery period and during the L-Dopa administration period (weeks 3-6).  
The L-DOPA administration period commences on Day 18 of the study in week 3.  AIMs 
testing sessions are executed during the L-Dopa administration period (weeks 3-6).  All 
behavioral testing sessions were terminated following the L-DOPA administration period.  
Behavioral testing sessions are indicated by open circles (pole test, rota-rod and cylinder 
test), and Xs (AIMs testing). 
 
Description of Behavioral Tests 
 Morris Water Maze  
A 10 day study was conducted to assess spatial learning in the Morris water maze.  
A circular tank (1.2 m diameter) was filled with water and made opaque by mixing the 
water with 4 to 8oz of water-soluble non-toxic white paint.  The tank was divided into 
four quadrants (N, S, E, W).  One plexiglass platform (10cm x 10 cm) was positioned in 
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the center of the quadrant at either the SW or NE positions and was made to be hidden 
(below water level) or visible (above water level).  Fig 10d shows the placement of the 
platform for each testing session.  The place acquisition task was carried out over five 
consecutive days (Day1-5) and each testing session consisted of three trials.  For each 
trial, an animal was placed at one of the sequential start positions, midway between each 
quadrant at the perimeter or the tank, beginning at NE position and ending at SE position.  
Time to find the hidden platform in the SW position was recorded.   The animals were 
allowed 120s to rest on the platform and between trials.  The maximum time for each trial 
was 120s.  To assess the animal’s spatial knowledge of platform location, the hidden 
platform was removed from the tank and the animal was given 60s to swim freely (Day 
6).  The time spent in each quadrant was recorded.  To assess visual cue learning, the 
hidden platform was replaced with a visible platform in the SW quadrant (Day 7) and NE 
quadrant (Day8-10).  The time to find the visible platform was recorded. 
  
Rota-Rod 
Motor coordination and balance were assessed using the Five Station Rota-Rod 
Stand Alone for Mouse (Med Associates Inc., St. Albans, VT).  One animal was placed in 
each lane on top of the rotating rod.  The dowel rod is gripped and allows animals to 
grasp the rod adequately to ensure that fall latency is not a result of slipping.  Once one to 
five animals were rested on the rod, the machine was turned on and set to a continuous 
accelerating speed of 2.5 to 25 rpm.  When the animal falls off the rotating rod, the 
weight of the animal is sensed on the platform and time spent on the rod is recorded.  
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Each mouse was tested a total of four trials per testing session.  The maximum trial time 
was 10 min.  Animals were given a 2 min rest between each trial.   
 
6-OHDA Surgery and Post-Operative Care  
Unilateral 6-OHDA injection at the left medial forebrain bundle (MFB) was 
performed to induce a unilateral lesion of dopamine neurons (Francardo et al., 2011). 
(Unilateral 6-OHDA lesioning was performed in the laboratory by a skilled technician.)   
Following unilateral 6-OHDA lesioning, mice received sub-cutaneous injections 
of sterile saline solution (0.1 ml/10g body weight), two times daily during the two week 
recovery period.  All lesioned mice showed difficulty eating and were force-fed 
International Delight Half-&-Half using a mouse feeding needle two times a day.  
International Delight Half-&-Half was also placed at the floor of the cages in original 
individual serve packages once a day during the ten day recovery period.  Following the 
recovery period, mice were provided food and water ad libitum.  To avoid food 
competition, mice of similar genotype and body weight were paired in the same cage.   
 
L-Dopa Treatment 
L-Dopa methyl ester and peripheral Dopa decarboxylase inhibitor benserazide-
hydrochloride (12mg/kg) (Sigma Aldrich) were dissolved in 2% Ascorbic acid and saline 
prior to use and stored for 24 hr at 4°C for next day use.  Mice received daily injection of 
L-Dopa over the 3 week L-Dopa administration period.  Administration of L-Dopa 
induced dyskinesia following injection. 
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Lesion Screening 
The efficacy of 6-OHDA lesioning was determined in two ways.  First, it was 
determined by turning ipsilateral to the lesion and second, by contralateral turning 
following L-Dopa adminstration.  Animals that did not display both indications of 
effective dopamine lesioning were removed from the study.  At 10 days post-surgery 
76% of mice demonstrated ipsilateral rotation.  Upon the first administration of L-Dopa, 
mice were reevaluated for contralateral rotation.  Out of the select mice that were 
considered to acquire an adequate 6-OHDA lesion, 48% of were observed to exhibit 
contralateral rotation following the administration of L-Dopa.  
 
AIMs 
Abnormal Involuntary Movements (AIMs) were evaluated as previously 
described (Lundlad et al., 2004).  The severity of dyskinesia was rated based on the AIMs 
scale.  The AIMs testing period extended over the twenty-one days during the L-Dopa 
administration period.  Each animal was observed for 1 min every 20 min, for a total of 7 
min during the 140 min testing session that followed the L-Dopa injection.  Animals were 
scored based on four behavioral categories (i) locomotive dyskinesia, which is a circular 
turning motion, or spinning towards the side contralateral to the lesion (ii) axial 
dyskinesia, which is twisted neck and back posture towards the side contralateral to the 
lesion while the animal is turning towards the contralateral side (iii) forelimb dyskinesia, 
which is dystonic movements of the forelimbs (vi) orolingual dyskinesia, which is jaw 
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movements with tongue protrusion.  Each behavioral sub-type of dyskinesia was scored 
0-4, based on severity (0 = none, 1 = occasional, 2 = frequent, 3 = continuous but 
interrupted by sensory distraction, 4 = continuous and not disrupted).  The maximum 
score per testing session is 128 (maximum score per 20 min observation period = 16; 
number of observation periods = 8).   
 
Assessment of motor performance in dopamine deficient mice 
Dopamine deficient mice underwent three types of behavioral tests: pole test, 
rota-rod test and cylinder test.  Behavioral tests were performed throughout the duration 
of the dyskinesia study.  All behavioral tests were performed prior in intact, 6-OHDA 
lesioned and subsequently L-Dopa treated mice.  During the twenty-one days of the L-
Dopa administration period, each behavior test was performed approximately 20 to 22 
hours following the last administration of L-Dopa.   
 
Pole Test 
The pole test was used to assess bradykinesia, motor coordination and balance.  
Each mouse was placed facing head-upwards at the top of a wooden pole covered with 
overlapping white grip tape (5mm diameter and 1m height).  The time for the animal to 
turn and orient downward, as well as the time to descend the pole was measured.  A score 
was given to assess the motor coordination of the animal as it descended down the pole.  
The following scale was used (1-20 s = 1; 20-40 s = 2; 40-60 s = 3; 60-90 s = 4; Spiral = 
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5; Freezing = 6; Sliding = 7; Falling = 8).  Five trails were performed with a maximum 
time down of 120 s.   
 
Rota-rod 
The rota-rod test was performed as described above.   
 
Cylinder Test 
The cylinder test was used to measure motor activity and limb asymmetry.  Each 
mouse was placed individually into a 500mL beaker.  The number forelimb contacts was 
recorded.  Use of left, right or both paws was noted.  Animals were not given time to 
habituate to the new setting.  One 5 min trial was performed per testing session. 
 
Tissue Collection and Preparation  
Animals were anesthetized with 90mg/kg ketamine and 4.5mg/kg xylene in PBS 
and administered 0.1ml/10g body weight via IP injection and transcardially perfused with 
4% paraformaldehyde.  Brain tissue was post fixed in 4% PFA for 2-4 hrs and transferred 
to 0.1M PBS 4°C for 24 hours.  Sectioning was performed on Vibratome Series 1000 
sectioning system at 22°C and stored in PBS at 4°C until processing by 
immunohistochemistry.   
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Immunohistochemistry 
Sagittal sections were cut on the vibratome at 50μm thickness and mounted on 
gelatin-coated glass slides.  Sections were placed in 0.3% Hydrogen Peroxide (H2O2) in 
PBS and incubated in the presence of primary antibody, monoclonal Mouse anti-Gad67 
antibody (MAB351; Millipore, Billerica, MA), dilution 1:5,000, or monoclonal Mouse 
anti-GFP antibody (MAB5406; Millipore, Billerica, MA) in 2% NHS and 0.1% Triton-X 
in 0.1M PBS.  Then, sections were incubated in a biotinylated secondary, horse anti-
mouse antibody (W1123; Millipore, Billerica, MA), dilution 1:250 in 2% NHS in 0.1M 
PBS.   The complex was detected with the Vectastain ABC kit complex (Vector Labs, 
Burlingame, CA) and DAB (Vector Labs, Burlingame, CA).  Sections were dehydrated 
and mounted with Eukitt (Calibrated Instruments Inc, Hawthorn, NY).  
Immunohistochemically labeled sections were visualized on a Nikon Eclipse E600 
microscope.   
 
Stereology 
Gad67 positively stained cells were visualized using Nikon Eclipse E600 
microscope and quantified using Stereo Investigator V. 10 software (MicroBrightfield, 
Williston, VT) (N=1, conditional knockout n=1 control n=1).  The estimated number of 
positive cells was determined using the optical fractionator probe and was carried out in a 
systematic and unbiased manner in the striatum and globus pallidus (GP).  Estimated cell 
population is reported as the estimated population using mean section thickness with 
counts.  Cell counting was performed in the striatum spanning 47 sections at 20x 
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magnification in a 1:5 series.  The counting frame for the striatum (x=600 y=600) and 
grid size (x=800 y=800) was optimized to count between 100 – 200 cells per animal with 
Gunderson CE (m=1) less than 0.1.  Cell counting was performed in the GP spanning 21 
sections at 20x magnification in a 1:3 series.  The counting frame for the GP (x=200 
y=200) and grid size (x=300 y=300) was also optimized to count between 100-200 cells 
per animal with Gunderson CE (m=1) less than 0.1.  Assessment of neuropil was 
performed by selecting punctate immunolabeled elements in the GP spanning 21 sections 
at 20x magnification in a 1:3 series.  The counting frame for neuropil in the GP (x=20 
y=20) and grid size (x=300 y=300) was optimized to count between 100-200 axons per 
animals with Gunderson CE (m=1) less than 0.1.  Guard zones of 5μm above and below 
were assigned to avoid inconsistency in section thickness.   
 
Densitometry 
Quantitative immunohistochemcial analysis of Gad67 labeling was performed 
using densitometry (N=2, conditional knockout n=1 control n=1). For quantitative image 
analysis of Gad67 staining, comparable levels of brain sections from both genotypes 
stained with Gad67 were assessed for optical density using Image J software (NIH, 
Bethesda, MD).  Average optical density was obtained for the striatum, GP and SNr. 
Optical density was measured in a 1:2 series. All images were captured at the same time 
in the same lighting conditions on a light box using Nikon Eclipse E600 microscope and 
stored as 8bit files.  Optical density was calibrated to Kodak wratten Gelatin Filter 
standards using the exponential function settings on Image J software.  Average mean 
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grey value was measured within each region of interest and is reported as the optical 
density of the region. 
Mean optical density of labeling over neuronal cell bodies was assessed in the GP.  
Each cell was individually selected as a region of interest using Image J software.  For all 
cells, the region of interest was assigned at 150% zoom and made to encompass the cell 
body and minimize background pixels.  Cell selection was performed in a 1:3 series.  Ten 
cells were randomly selected within the section.  Conditions were optimized to select 80 
cells per animal.  All images were obtained at the same time using the same conditions at 
10 x magnification using a Nikon Eclipse E600 microscope.  Digitized mosaic images 
were obtained using surveyor microscope software (Objective Imagining, Cambridge, 
United Kingdom).  Optical density was measured on digitized images using the 
uncalibrated optical density function in Image J and is reported as the optical density of 
the cell.  Internal normalization was applied to each cell within a section by measuring 
the uncalibrated optical density of a constant circular area of white matter in the striatum 
in the section. 
 
Patch Clamp 
Whole cell patch clamp was used to record spontaneous IPSCs from striatal 
MSNs.  Experiments were performed in 200µm coronal sections from conditional 
knockout (n=2) and control (n=1) mice.  GABAA mediated IPSCs were recorded at a 
membrane potential (Vh ) held at Vh= -60mV or Vh = -80mV.  (Whole cell patch clamp 
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recordings were performed by Dr. Luebke). Data was analyzed with Mini-Analysis 
software (Synaptosoft Inc., Decatur, GA).  
 
Statistical Analysis 
All statistical comparisons (ANOVA, two-way ANOVA, repeated measures two-
way ANOVA and unpaired T-test) and all graphical representations were generated using 
GraphPad Prism software.  Statistical values are not included where comparisons were 
not significant.  
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RESULTS 
 
Molecular and electrophysiological characterization of conditional knockout mice  
Genotyping 
Verification of the genotype was confirmed by PCR analysis.  The Gad1 and 
Gpr88frt genes were amplified by using PCR primers based on reported primer 
sequences.  The PCR products for Gad1 included a Gad1lox band (750bp), a Gad1 null 
band (200bp) and positive band for Gad1 (520bp) (not shown) (fig 5a).  The PCR 
products for Gpr88frt included a Gpr88frt positive band (300bp) and a Gpr88frt null 
band (200bp) (fig 5b).  Genotypes were confirmed by the PCR product.  All mice in this 
study contained positive Gad1lox and Gad1 null alleles, whereas only conditional 
knockout mice contained a positive Gpr88frt allele.   
 
Fig 5. PCR genotyping.  PCR genotyping of mice generated by breeding 
Gpr88CreGFP:: Gad1+/Δ with Gad1lox/lox mice is designated by (A) Gad1 alleles: 
Gad1flox band (750 bp), Gad1 null band (200 bp) and Gad1+ (520 bp; not shown) and 
(B) Gpr88frt alleles: positive Cre band (300 bp) and Cre null band (200bp). 
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Gpr88 immunohistochemistry 
Immunohistochemistry with a monocolonal anti-GFP antibody was used to 
analyze GFP reporter expression in conditional knockout mice.  GFP immunolabeling 
was most prominent in the striatum (caudate putamen and nucleus accumbens) and in the 
olfactory tubercle (fig 6 b-c). Strong labeling could also be seen in the somatomotor 
region of the cerebral cortex (fig 6a). Finally, less prominent and scattered labeling was 
detected in other brain regions (table 1) including the ectorhinal area, entorhinal area, 
visual cortex, hippocampus and amygdala. 
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Fig 6. Immunohistochemistry of Cre-mediated GFP reporter expression.   
Immunohistochemical detection of GFP expression in cortex (A) striatum (B) and 
olfactory tubercle (C). 
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Table 1. Conditional knockout Cre-mediated recombination GFP reporter 
expression. Regions showing immunolabeling of GFP, signifying Gpr88Cre mediated 
recombination in conditional knockout mice.  The percent of GFP labeled cells was 
estimated in each positively labeled region observed under bright-field microscopy.  
 
Cortex  Main Olfactory Bulb ++ 
Caudal Somatomotor Area ++++ Anterior Olfactory Nucleus ++ 
Frontal Pole ++++ Striatum  
Somatosensory Area  Caudate Putamen ++++ 
Layer VI ++++ Nucleus Accumbens ++++ 
Layer V +++ Fundus of Striatum ++ 
Layer IV ++ Substantia Innominata + 
Layer II/III ++++ Bed nuclei of stria terminalis + 
Layer I + Striatum Like Amygdalar Nuclei + 
Rostral Visual Area  Anterior Amygdalar Area ++ 
Layer VI ++++ Olfactory Areas  
Layer V ++++ Piriform Amygdalar Area ++ 
Layer IV ++ Cortical Amygdalar Area Anterior  ++ 
Layer II/III + Cortical Amygdalar Area Posterior  ++ 
Layer I +/- Piriform Area ++ 
Visceral Area + Olfactory tubercle +++ 
Gustatory Area +/- Nucleus of the Lateral Olfactory Tract ++ 
Agranular Insular Area Dorsal +/- Diagonal Band Nucleus + 
Agranular Insular Area Ventral +/- Hypothalamus +/- 
Angular Insular Area +/- Inferior Colliculus ++ 
Orbital Area +/- Cerebellum  
Claustrum + Granular Layer ++++ 
Corpus Collosum ++ Purkinje Cell Layer ++++ 
Ectorhinal Area ++++ Interposed nucleus +++ 
Entorhinal Area ++++ Fastigial nucleus +++ 
Retrosplenial Area Dorsal ++++ Brain Stem ++ 
Retrosplenial Area Ventral ++++ +/-  ≈ Scattered Cells  
Postsubicilum  ++++ +  ≈ 25% of cells  
Hippocampus +/- ++  ≈ 50% of Cells  
Dentate Gyrus Granular Layer +++ +++  ≈ 75% of Cells  
CA3 Pyramidal Layer +++ ++++  ≈ All Cells  
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Gad67 immunohistochemistry  
Gad67 immunohistochemistry revealed few labeled cell bodies in the striatum of 
control and conditional knockout mice.  To assess the extent of Gad1 deletion, 
densitometric measurements of Gad67 immunohistochemical labeling was performed on 
sagittal brain sections in the striatum, GP and SNr (fig 7).  Analysis of optical density in 
each brain region was performed at the same level and compared between groups.  Gad67 
immunohistochemistry revealed on average a 23% decrease in Gad67 expression in the 
striatum and 29% in the SNr across all parasagittal levels in conditional knockout mice 
(fig 7).  There was no difference in the overall optical density (measured over both 
neuropil and cell bodies) of Gad67 labeling in the GP.  However, the optical density of 
Gad67 specifically measured over immunolabeled neuronal cell bodies in the GP of the 
conditional knockout mouse was enhanced compared to the control mouse (3.45 ± 0.051 
in knockout vs. 2.65 ± 0.07 in control; p<0.001; unpaired t-test). 
 53 
 
Fig 7. Immunohistochemistry of Gad67. Immunohistochemical detection of Gad67 in 
the control (A-C) and knockout (D-F).  A higher intensity of Gad67 immunolabeling was 
detected in the striatum (A) and SNr (B) of the control, compared to the striatum (D) and 
SNr (E) of the conditional knockout.  A higher intensity of Gad67 immunolabeling was 
observed GP neurons of the conditional knockout (F) than in GP neurons of the control 
(C).  Note labeling intensity.  
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The finding that Gad67 expression appeared stronger in a few striatal neurons in 
control and knockout mice is consistent with previous reports that Gad67 is highly 
expressed in striatal interneurons but not in striatal projection neurons (Kita, 1990).  In 
order to determine if Gad1 loss occurred in the small population of GABAergic presumed 
interneurons in addition to striatal projection neurons in our experiments, we measured 
by quantitative stereological analysis the number of intensely labeled neurons in the 
striatum. The estimated numbers of intensely Gad67 labeled neurons in the striatum were 
not significantly different between control and conditional knockout mice (2,660±13.2 in 
knockout vs. 2,317±12.9 in control).  This result suggests that Gpr88 is not widely 
expressed in striatal interneurons and that Gad67 was not significantly lost in striatal 
GABAergic interneurons.    
Gad67 immunolabeling could also be detected in the GP.  Quantitative 
stereological analysis indicated that more Gad67 immunopositive cells were visible in the 
GP of KO compared to control mice (1,950±12.9 in knockout vs. 1,260±10.0 in control).  
Neuropil labeling was also assessed in the GP by counting the number of punctuate 
immunolabeled elements.  The estimated number of labeled elements was not 
significantly different between knockout and control mice (192,787±13.6 in knockout vs. 
177,057±11.8 in control). This observation appears consistent with the result described in 
previous paragraphs that the overall optical density over the GP measured over both 
neuropil and cell bodies is not significantly different between control and conditional 
knockout mice. 
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Deletion of Gad1 reduces frequency and increases decay of spontaneous IPSCs in 
MSNs 
Next, to test the how the deletion of GAD1affects GABAergic transmission in 
striatal medium spiny neurons (MSNs), whole-cell-patch-clamp recordings were 
performed in coronal sections from conditional knockout and control mice. These 
recordings were carried out by Dr. Jennifer Luebke from the department of Anatomy and 
Neurobiology at Boston University School of Medicine.  Spontaneous IPSCs were 
recorded in striatal medium spiny neurons (MSNs).  Whole-cell-patch-clamp recordings 
were performed at command potential Vh = -60mV and Vh = -80mV.  The MSNs were 
infused with dye and visualized during the recording (fig 8).  Deletion of Gad1 reduced 
spontaneous inhibitory postsynaptic current (IPSC) frequency at Vh = -60mV (p=0.041; 
unpaired t-test) and Vh = -80mV (p=0.0303; unpaired t-test; fig 9a,b) and increased IPSC 
decay at  Vh = -60mV (p=0.0183; unpaired t-test) and  Vh = -80mV (p=0.0122; unpaired 
t-test; fig 9a,b).  These preliminary results indicate that a deletion in Gad67 may result in 
a decreased in IPSC amplitude in striatal MSNs.  Since spontaneous GABAergic IPSCs 
can still be observed after the deletion of Gad67, it can hypothesized that remaining 
GABAergic inhibitory synaptic activity in the striatum depends on Gad65 activity in 
striatal MSNs, which is also involved in GABA synthesis and release in striatum.  
Deletion of Gad67 in the striatum did not result in changes in spontaneous IPSC rise or 
area.    
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Fig 8. Medium spiny neuron.  Confocal representative image of medium spiny neurons 
in the striatum (A) and at a higher magnification (B).  Note the dendritic spines.   
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Fig 9.  Deleting Gad1 in the striatum reduces IPSC frequency and increases IPSC 
decay.  Frequency, amplitude, rise, decay and area of spontaneous IPSCs from whole-
cell-patch-clamp recordings.  Medium spiny neurons (MSNs) recorded at a command 
potential (Vh) Vh = -60mV (A) (MSNs from striatal slice conditional knockout
 n = 6, 
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control n =7; *p<0.05 unpaired t-test) or Vh= -80mV (B) (MSNs from striatal slice n=5, 
control n=6; *p<0.05 unpaired t-test).  
 
Behavioral Characterization of Gad1 Deletion in the Striatum 
Morris water-maze 
Mice were trained in the Morris Water Maze (MWM) to determine their ability to 
learn the position of a hidden escape platform.  During the first five days of the study 
(Day1-5), mice were trained in the place acquisition task to find the hidden platform in 
the SW quadrant (fig 9a).  Conditional knockout mice exhibited longer escape latencies 
for the hidden platform throughout the training period (F(1,60)=15.18; p=0.0002; 2-way 
ANOVA).   
Assessment of location retention of the hidden platform was performed on Day 6 
(fig 9b).  The hidden platform was removed from the SW quadrant and mice were given 
60s to attempt at locating the platform.  Control mice spent more time in the SW quadrant 
than any other quadrant [NE vs. SW (p=0.001; unpaired t-test), SE vs. SW (p=0.0004; 
unpaired t-test) and NW vs. SW (p=0.019; unpaired t-test).  Conditional knockout mice 
also spent the most time in the SW quadrant, but there were no significant differences 
between the time spent in the SW and NW quadrants. This indicates that knockout mice 
did not remember the position of the hidden platform as well as controls.    
Mice were trained in visual cue learning during the last four days of testing (Day 
7-10; fig 9c).  On Day 7, the visible platform was placed in the SW quadrant.  The visible 
platform was transferred to the NE quadrant Days 8-10 of testing.  Both groups 
demonstrate similar escape latencies for the visible platform in all testing periods.  
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Similar performance in the visual cue task indicates swim speed is not different between 
control and conditional knockout mice.   
 
 
Fig 10.  Spatial learning and place acquisition.  The effects of the deletion of Gad1 in 
memory and learning are depicted through escape latency for the hidden platform and 
place learning (conditional knockout n = 9, control n = 6; *p<0.05 unpaired t-test).  
Escape latency for the hidden platform (A), location retention, or time spent in each 
quadrant during place acquisition task (B), escape latency for visible platform (C).   
Representation of platform location in NE or SW quadrants in the Morris water maze 
(D).    
 
Motor Coordination and Balance  
Motor coordination and balance were assessed using the rota-rod test.  Both 
groups were given 4 trials during one day of testing. There was no difference in fall 
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latency between the two groups throughout the four trials (fig 10).  Over the course of the 
four trials, both control and knockout mice displayed a longer fall latency during trial 4 
than during trial 1 (p=0.0185 and p=0.00715, respectively; unpaired t-test).  
 
Fig 11. Motor performance in intact mice.  The time spent on the rod during four 
consecutive trials in one testing session (conditional knockout n = 9, control n = 6; 
*p<0.05 unpaired t-test).  
 
L-DOPA Induced AIMs   
L-Dopa administration to 6-OHDA lesioned mice resulted in dyskinesia.  The 
extent of dyskinesia was scored on the AIMs scale for locomotive, axial, limb and 
orolingual dyskinesia during a 140min testing session or until dyskinesia subsided.  The 
temporal profile of cumulative AIMs scores per 20 min intervals revealed no difference 
in dyskinetic behavior between conditional knockout and control mice (fig 11a).  Both 
groups reached peak AIMs severity between 40 and 60 min following L-Dopa 
administration.  The severity of AIMs is similar between conditional knockout and 
control mice.  There was no overall difference in the development and maintenance of   
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dyskinesia.  Both groups exhibited the same trending in locomotive AIMs and combined 
Ax/Lb/Ol AIMs.  
  
Fig 12. L-Dopa-induced AIMs.  AIMs scores were evaluated during the L-DOPA 
administration period. The duration and severity of dyskinesia at each 20 min interval (A) 
sum of locomotive (B) sum of axial, limb and oralingual AIM scores per testing session 
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(C) are depicted. Values in A represent the average locomotive, axial, limb and oralingual 
AIM scores per testing session observed throughout the duration of the study. 
 
Motor impairment following dopaminergic denervation and after l-DOPA 
Motor coordination, balance and locomotor activity were assessed in intact, 6-
OHDA lesioned and subsequently L-Dopa treated mice.  During the L-Dopa 
administration period, mice were subject to motor testing approximately 22 hours 
following the last administration of L-Dopa.   
 
Pole Test  
The pole test was used to assess motor coordination and balance, which may 
indicate bradykinesia or hypokinesia.  Mice were placed facing upwards on a wooden 
pole and allowed to climb down to an open cage.  A score was assigned to indicate motor 
performance (fig 13a).   The amount of time to turn and orient downwards, as well as the 
time down to descend from the pole was recorded (fig 13b).  Intact mice show no 
difference in score (fig 13a), time down (fig13b), or time to reorient while descending the 
pole (data not shown).  Dopaminergic denervation by 6-OHDA lesioning led to a marked 
impairment in score (p=0.00168 for knockout and p=0.0213 in control; unpaired t-test) 
and increased time down in both control and conditional knockout mice (p=0.0235 for 
knockout and p=0.00152 for control; unpaired t-test).  Dopamine deficient mice were 
observed to exhibit spiraling, sliding and falling as they descended the pole.  Spiraling 
was observed ipsilateral to the lesion in all dopamine deficient mice.  The increased score 
and time down following 6-OHDA lesioning was maintained with the subsequent 
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administration of L-Dopa in both conditional knockout and control mice (p=0.01885 for 
knockout and p=0.00727 for control; unpaired t-test; fig 13a, b).  Spiraling was observed 
ipsilateral to the lesion during the L-Dopa administration period.   
 
Rota-rod 
As mentioned previously, there was no deficit in rota-rod performance in intact 
mice.  6-OHDA lesioning alone did not impair motor performance in the rota-rod in 
either conditional knockout or control mice.  Treatment with L-Dopa improved rota-rod 
performance in control mice (F(1,3)=13.87; p=0.0029; 2-way ANOVA), but not in 
conditional knockout mice.   
 
Cylinder Test 
The cylinder test assesses a level of motor activity based on the number of 
forelimb contacts made upon rearing.  Intact mice demonstrated similar frequency of 
forelimb contacts.  Following 6-OHDA lesioning, both groups were observed to decrease 
the amount of total contacts made upon rearing (p=0.0246 for knockout and p=0.0381 for 
control; 2-way ANOVA fig 13d).  L-Dopa administration does not impact rearing.  
Instead, the decreased activity is maintained for both groups during the L-Dopa 
administration period.  
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Fig 13. Dopaminergic denervation impairs motor performance.  Motor coordination 
was assessed using the rota-rod, pole test and cylinder test; conditional knockout n = 2, 
control n = 3; *P<0.05 between groups; #P<0.05 for both groups between pre-test and 6-
OHDA lesion.  The average per testing session prior to unilateral 6-OHDA lesion (Pre), 
following the 6-OHDA lesioning and recovery (Post, Post(2)) and during the L-Dopa 
administration period (D5-21) was observed for (A) the pole test score and (B) time 
down, (C) rota-rod (sec) and (D) total forelimb use in the cylinder test.   
 
Forelimb Asymmetry  
The cylinder test was also used to determine forelimb asymmetry resulting from 
dopamine denervation and L-Dopa treatment.  Due to the significant decrease in total 
forelimb contacts following the 6-ODHA lesion, unilateral and bilateral forelimb use was 
calculated as a percentage of total forelimb use.  Intact mice demonstrate similar bilateral 
forelimb use upon rearing.  Bilateral forelimb use continues in both groups following 
dopaminergic denervation however, conditional knockout developed a preference for 
 65 
unilateral forelimb use following 6-ODHA lesioning (F(2,6)-21.27, p=0.0019; 2-way 
repeated measures ANOVA).  Unilateral forelimb use continued during the L-Dopa 
administration period (F(2,6)=20.62, p=0.002; 2-way repeated measures ANOVA).  
Similarly, subsequent L-Dopa administration led to a development in unilateral forelimb 
bias control mice (F(2,3)=15.50, p=0.0262; 2-way repeated measures ANOVA).  
However, neither ipsilateral nor contralateral forelimb preference was detected in either 
group throughout the duration of the study. 
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DISCUSSION 
 
 In this study, we investigated the electrophysiological and behavioral effects of 
deleting Gad67 in neurons co-expressing Gpr88Cre-GFP and the floxed Gad1 gene.  
Gpr88 is a striatum specific G-coupled receptor expressed in striatonigral and 
striatopallidal MSNs (Hisatsune et al., 2013; Quintana et al., 2012; Massart et al., 2009). 
However, GPR88 is also expressed to a lesser extent in the olfactory tubercle, cortex, 
amygdala and brain stem.  Therefore, it is likely that Gad67 was predominantly deleted in 
striatal MSNs using Cre/loxP mediated recombination of exon 2 of Gad1.  Striatal 
function requires GABAergic signaling by striatonigral and striatopallidal MSNs.  
However, the contribution of GABAergic signaling to behaviors attributed to the striatum 
and to basal ganglia neurodegenerative disease is not completely understood.  In this 
work, we document that mice with a deletion in striatal Gad67 exhibit a number of 
deficits including impaired spatial learning in the Morris water maze. However, we also 
document that Gad67 deletion does not lead to bradykinesia, hypokinesia. In addition, 
our results show that a deletion in striatal Gad67 in the direct and indirect pathways does 
not decrease dyskinesia induced by l-DOPA in dopamine-depleted mice.     
 
Regional expression of Gpr88  
Gpr88 expression was visualized by Cre-mediated GFP reporter expression and 
was observed using a monoclonal anti-GFP antibody, which provided 
immunohistochemical amplification of the GFP signal. The present findings confirm that 
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Gpr88 is prominently expressed in the striatum (caudate putamen and nucleus 
accumbens) and olfactory tubercle (Hisatsune et al., 2013; Quintana et al., 2012; Massart 
et al., 2009; Logue et al., 2009; Mizushima et al., 2000).  Additionally, Gpr88 expression 
was confirmed in the cortex, amygdala (Massart et al., 2009) and brain stem (Quintana et 
al., 2012).  No labeling was observed in the GP or SNr, similar to previous reports 
(Hisatsune et al., 2013, Quintana et al., 2012; Massart et al., 2009).  
Double labeling studies against Gad67 and parvalbumin suggest that intense 
Gad67 immunostaining is restricted to striatal interneurons (Kita 1990).  Consistently, 
PCR (Quintana et al., 2012) and in situ hybridization (Massart et al., 2009) studies show 
that Gpr88 mRNA expression is co-expressed with the markers of striatal projections 
neurons dynorphin or substance P and encephalin.  Additionally, Quintana and colleagues 
showed that when Gpr88CreEGFP mice were crossed with Td Tomato reporter mice, Td 
tomato reporter expression filled striatal projection MSNs to the GP and SNr (Quintana et 
al., 2012).  This result suggests that Gpr88 is expressed in MSNs in the direct and indirect 
pathways but not striatal interneurons.  Our results are consistent with the assumption that 
Gpr88Cre is not expressed in striatal interneurons since the number of Gad67 positively 
labeled neurons in the striatum, which have been shown to be striatal interneurons, was 
not statistically significantly different between conditional knockout and control mice.   
Because Gpr88 is preferentially expressed near synapses in postsynaptic elements 
such as dendrites and spines of striatonigral and striatopallidal MSNs (Massart et al., 
2009), Gpr88 may play a role in modulating striatal input to the direct and indirect 
pathways and influence basal ganglia function.  Further defining the role of the Gpr88 
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receptor in MSNs would help identify the post synaptic molecular mechanisms that 
influence basal ganglia activity at the level of the striatum.   
 
Gpr88 expression is regulated during development  
Cre-mediated GFP reporter expression revealed the activity of Gpr88Cre 
recombinase activity at the time the mice were sacrificed.  However, Gpr88Cre 
recombinase could have been expressed throughout development or at specific 
developmental stages in addition to adulthood.  In that case, once Cre recombinase 
excises exon 2 of Gad1 in a cell where Gpr88Cre is expressed, all descendants of the cell 
carry the spliced version of the Gad1 gene.  Changes in early development are passed 
from progenitor cells to daughter cells and permanent gene modification is extended into 
adulthood, projecting the pattern of development from which cells that express Gpr88 
during development arise.  Therefore, the pattern of GFP expression in the adult mouse 
brain may be less widespread than the pattern of Gad67 loss.  Results in our laboratory 
show that Gad67 protein levels are not significantly decreased in the cerebellum or 
cerebral cortex, even though GFP expression was detected in these brain regions. This 
suggests that GFP expression in other brain regions may not occur in GABAergic 
neurons.  In addition to the reported expression of Gpr88 as previously mentioned, GFP 
reporter immunolabeling indicated prominent Gpr88 expression throughout the mouse 
brain and brain stem.  First, a particular pattern of Cre-mediated GFP expression was 
observed in the cortex.  Labeling in the cortex was observed in the somatosensory, 
somatomotor and visual areas in all layers, with the highest density of labeling in the 
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caudal regions of the somatomotor area of the cortex (fig 6a).  GFP expression was also 
observed in the rostral visual area and adjacent ectorhinal and entorhinal areas.  Despite 
sparse labeling throughout the hippocampus, strong labeling was confirmed in the 
granular layer of the dentate gyrus and pyramidal layer of CA3.  In the cerebellum, GFP 
labeling was observed in the Purkinje and granular layers, and within the interposed 
nucleus.  Labeling was also observed throughout the brain stem.  Additional regions were 
observed to exhibit more diffuse GFP labeling and are listed in table 1.  In a study 
performed by Quintana and colleagues, Gpr88Cre-EGFP mice were crossed with Td 
tomato reporter mice, which also revealed reporter expression in regions that do not 
express Gpr88 in adulthood, indicating that Gpr88 expression is highly expressed during 
development (Quintana et al., 2012).  Another study indicated that the expression of 
Gpr88 is differentially regulated in the different regions of the striatum from juvenile age 
to adulthood (Van Waes et al., 2011).  Together these studies confirm that Gpr88 
expression is differentially expressed during development in regions within and besides 
the striatum.  Future studies are required to understand the developmental regulation of 
Gpr88 throughout various brain regions. 
 
Deletion of Gad67  
The downregulation of Gad67 in conditional knockout mice was confirmed by the 
optical density measurements of Gad67 immunolabeling and western blotting.  GFP 
reporter expression was observed in the striatum (fig 6 b), indicating that Cre-mediated 
recombination events took place.  These results are consistent and provide compelling 
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evidence that exon2 of Gad1 was excised in the striatum via Cre/loxP recombination.  
Furthermore, the deletion of Gad67 in striatal MSNs revealed a decrease in IPSC 
frequency and increased IPSC decay.  A recent study showed that deletion of Gad1 
reduces GABA levels and mIPSC amplitude and frequency in hippocampal cell cultures 
of Gad1-/-, or Gad1 homozygous null mice (Lau and Murthy, 2012).  Similarly, striatal 
MSNs with a deletion in Gad67 exhibit decreased spontaneous IPSC frequency.  Future 
patch clamp studies in conditional knockout mice may reveal a decrease in IPSC 
amplitude in striatal MSNs with a deletion in Gad67.   The decrease in Gad67 expression 
and IPSC frequency demonstrate impaired GABAergic function in striatal MSNs. 
 
Altered Gad67 expression in basal ganglia following down-regulation of striatal 
Gad67 
We found that deleting Gad67 expression in striatal MSNs induces increased 
Gad67 in the GP and decreased Gad67 in the SNr.  In the Gp, however, densitometric 
measurements over the whole GP revealed no change in optical density in conditional 
knockout mice, but an increase in the optical density of cell bodies. This effect was 
paralleled by an increased number of Gad67 immunolabeled GP neurons. The 
significance of these apparently contradictory results remains hypothetical. It is possible 
however, that these reflect a dual effect of the Gad67-deletion on the axon terminals 
originating from the striatum and on the intrinsic cell bodies in the GP.  Indeed, the loss 
of Gad67 in striatopallidal neurons would be expected to reduce Gad67-positive neuropil 
labeling in the GP.  However, because striatopallidal neurons inhibit GP neurons, a 
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decreased inhibition from the striatum will result in a de-inhibition of GP neurons and 
hence an increase in Gad67 expression in GP GABAergic cell bodies.  Thus, the 
decreased labeling in the neuropil combined with the increased labeling in the cell bodies 
could oppose each other and result in no net effect in the GP as measured over the whole 
area of the nucleus by densitometry.  Thus, our results suggest that a deletion of Gad67 in 
striatopallidal MSNs results in a compensatory increase in the number and intensity of 
Gad67 immunolabeled GP neurons and therefore in a decreased striatopallidal output and 
an increased GABAergic output from the GP.   
Enhanced GABAergic signaling from the GP would inhibit the STN, which sends 
excitatory glutamatergic input to the SNr.  Thus, loss of Gad67 in striatopallidal neurons 
may result in increased inhibition of STN neurons and decreased excitation from the STN 
to the SNr and entopeduncular nucleus.  Additional investigation into STN activity would 
provide a more thorough understanding of the signaling modifications observed.  
 
Gad67 modifies learning and memory 
Our results demonstrate that deleting Gad67 in striatonigral and striatopallidal 
MSNs compromises spatial learning in the Morris water maze.  Similar to our results, 
mice with dorsomedial striatum lesions (Devan et al., 1999) and Gpr88 knockout mice 
demonstrate impaired spatial learning in the Morris water maze (Quintana et al., 2012).  
Lesion studies suggest that the striatum is involved in learning that is dissociated from 
hippocampus-based learning when the task involves acquisition of spatial information 
(Yin and Knowlton, 2006; Packard and Knowlton, 2002).  A recent study demonstrated 
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that the dorsomedial striatum supports the initial acquisition of place-learning in the 
Morris water maze (Woolley et al., 2013).  Furthermore, impairment in striatal signaling 
may result in deficits in learning and memory.  Quintana and colleagues observed that a 
loss of Gpr88 in striatonigral and striatopallidal MSs caused enhanced excitability in 
MSNs, disrupting normal GABAergic signaling in the direct and indirect pathways.  The 
enhanced excitability of striatal MSNS led to an overall increase in neuronal firing in 
Gpr88 knockout mice, which may impair learning due to an imbalance between striatal 
signaling in the direct and indirect pathways (Lovinger, 2012).  Therefore, any 
impairment in striatal signaling in the direct and indirect pathways of the dorsomedial 
striatum may cause impairment in spatial learning.     
 
Deletion of striatal Gad67 does not affect motor performance 
 Deleting Gad67 in striatonigral and striatopallidal MSNs did not result in 
bradykinesia or hypokinesia.  Instead, results gathered in the laboratory show that mice 
are hyperkinetic. Gpr88 knockout mice and mice with a deletion in Gad67 in DRD1 
containing striatal MSNs exhibit decreased fall latency and lack of improvement in 
subsequent trials in the rota-rod and inverted hanging wire grip test (Quintana et al., 
2012; Heusner et al., 2008).  The finding that loss of Gad67 in both striatal output 
neurons does not lead to deficits in motor performance suggests that the effects of loss in 
the direct pathway are opposed by loss in the indirect pathway, resulting in no-net effect.  
It is well known that activation of the indirect pathway is hypokinetic.  Therefore the loss 
of Gad67 in the indirect pathway may explain the hyperkinesia seen in our laboratory.  In 
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any case, our results indicate that loss of Gad67 in both direct and indirect pathway 
neurons does not significantly affect global motor performance.  It is possible, however, 
that loss of Gad67 in both striatal output pathways may alter movement initiation or 
movement selection, but these parameters were not examined in our studies. 
 
6-OHDA lesion causes motor disturbance 
Dopaminergic denervation in animal models is most commonly achieved by a 
unilateral lesion with dopaminergic neurotoxins, such as 6-hydroxy-dopamine (6-OHDA) 
or  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in order to mimic the 
symptomatology of Parkinson’s Disease (Schober, 2004).  Injection of 6-OHDA to the 
medial forebrain bundle causes 70% to 90% loss of dopamine (Pothakos et al., 2009).  
Adaptive changes at spared dopamine neurons compensate for the marked decrease in 
dopamine by increased synthesis and release of dopamine; as such, animals recover some 
voluntary actions and are able to maintain body weight (Zigmond et al., 1990).  Loss of 
striatal dopaminergic innervation induces hypersensitivity of postsynaptic dopamine 
receptors in the striatum ipsilateral to the lesion (Corvol et al., 2004) and causes function 
asymmetry, observed as ipsilateral rotation in response to dopamine-releasing agents or 
contralateral rotation when elicited by L-Dopa or direct dopamine receptor agonists 
(Ungerstedt, 1976).  Contralateral rotation induced by L-Dopa occurs only after 
approximately 90% of dopaminergic SNc neurons are lesioned (Deumens et al., 2002).   
Studies show that 6-OHDA lesioned animals consistently show impairment in the 
ability to use contralateral limbs in movement and postural adjustments (Schallert et al., 
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1992).  Prior studies show that mice with a unilateral 6-OHDA lesion develop forelimb 
bias and prefer using the ipsilateral forelimb (Galjch et al., 2012; Francardo et al., 2011; 
Iancu et al., 2005).  All lesioned mice used in this study developed a preference for 
unilateral forelimb use as opposed to using both forelimbs to contact the glass cylinder 
upon rearing.  However, neither 6-OHDA lesioned conditional knockout nor control mice 
demonstrated forelimb bias.  Due to the preliminary nature of our results, it is suspected 
that all lesioned mice will demonstrate forelimb bias with further testing.   
6-OHDA-lesioned conditional knockout mice demonstrated motor impairment 
compared to the control, as indicated by the rota-rod test.  This finding is consistent with 
published evidence that dopamine depletion or blocking dopamine receptors in animal 
models or in PD patients causes disturbances in motor behavior exhibited by extreme 
slowness of movement (bradykinesia), delay in the initiation of movements (akinesia) 
and decrease in the extent of movement (hypokinesia).  Factors that contribute to 
impaired movement include rigidity, tremor, muscle weakness, movement variability, 
and bradyphrenia or slowness of thought (Berardelli et al., 2001).  Decreased motor 
performance indicates that lesioned mice were affected by hypokinesia, since they were 
prone to fall or slide in the pole test and required more time to descend the pole. The 
motor disorders in dopamine-depleted animals are explained by a depression of striatal 
direct outputs and an overactivation of striatal indirect outputs. The lack of motor 
improvement in Gad67-deficient mice suggests that the loss of Gad67 in indirect pathway 
neurons is not sufficient to reverse the motor disorders induced by the 6-OHDA lesion of 
dopamine neurons. Therefore, altered striatal GABAergic signaling in the direct and 
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indirect pathways may contribute to the motor deficits seen in dopamine depleted 
animals.  
 
Deletion of Gad67 in the striatum does not decrease the severity of dyskinesia 
In the striatum, Gad67 is increased following dopaminergic denervation and 
further enhanced following subsequent L-Dopa administration (Horvath et al., 2011; Katz 
et al., 2005; Bacci et al., 2002; Carta et al., 2001, 2003). L-Dopa administration to 6-
OHDA lesioned rodents increases Gad67 and Gad56 in striatonigral MSNs, and to a 
lesser extent Gad67 in striatopallidal MSNs (Yamamoto and Soghomonian, 2009; Katz et 
al., 2005; Nielsen and Soghomonian, 2004).  Co-administration of a glutamate 
metabotropic mGluR5 antagonist and L-Dopa reduced the severity of dyskinesia and 
opposed the increases in Gad67 and Gad65 (Yamamoto and Soghomonian, 2009), in 
addition to opposing increased nigral GABA release that is also observed in LID (Mela et 
al., 2007).  Therefore, increased Gad67 and GABAergic output from the striatum 
contribute to dyskinesia (Rangel-Barajas et al, 2011, 2008; Yamamoto et al., 2006).  
However, our results indicate that the deletion of Gad67 in striatonigral and 
striatopallidal MSNs does not attenuate dyskinesia.  Even though L-Dopa or dopamine 
receptor agonists facilitate the inactivation of striatopallidal MSNs by decreasing 
GABAergic signaling, lesser changes in Gad67 expression are observed in PPE-negative 
neurons than in PPE-positive neurons (Carta et al., 2003; Nielsen and Soghomonian, 
2004). Additionally, changes in GABAergic activity do not appear in the GP in 
dyskinetic animals (Mela et al., 2007).  Deleting Gad67 in striatonigral and striatopallidal 
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MSNs dampens the activity of the direct and indirect pathway.  However, total inhibition 
striatopallidal MSNs may have reduced the thalamic inhibition required to control 
dyskinetic involuntary movements.   
 
Future studies 
Future studies are required to determine whether GABAergic transmission in the 
striatum is involved in l-DOPA-induced dyskinesia.  A recent study demonstrated that 
co-activation of the direct and indirect pathway MSNs is required for motor initiation 
(Cui et al., 2013).  Pathologic changes in GABAergic signaling, such as those seen in 
Parkinson’s disease may only be corrected if GABAergic transmission is returned to 
normal, such as by the restoration of basal Gad67 expression in the striatum.  RNA 
interference vectors against Gad67 reduced elevated levels of Gad67 in dopamine 
depleted rats, which normalized neuronal activity, as indicated by mtCO1 protein levels 
in the striatum (Horvath et al., 2011).  This method of normalizing Gad67 expression in 
the striatum may be useful in determining whether a correction in Gad67 expression can 
reinstate normal GABAergic transmission and whether GABAergic transmission is 
responsible for normal initiation of motor movements.    
Increasing evidence indicates that the direct pathway is involved in the induction 
and maintenance of dyskinesia (Fisone and Bezard, 2011).  Animals with dyskinesia 
develop enhanced hypersensitivity and elevated expression of DRD1(Fisone and Bezard, 
2011), which results in greater activation of DRD1 and  production of cAMP to release 
more GABA into the synaptic cleft by direct pathway neurons (Rangel-Barajas et al, 
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2011; Arias Montano 2007, Nava Asbell 2007; Yamamoto et al., 2006).  On the other 
hand, changes in GABAergic activity are not detected in the globus pallidus (GP) in 
dyskinetic animals (Mela et al., 2007).  Based on these previous studies, it is possible that 
downregulating Gad67 expression selectively in striatonigral neurons will be able to 
prevent L-Dopa-induced dyskinesias.  
  
 78 
LIST OF JOURNAL ABBREVIATIONS 
 
Ann Neurol    Annals of Neurology 
Ann NY Acad Sci   Annals of the New York Academy of Science 
Arch Neurol    Archives of Neurology 
Behav Brain Res   Behavioral Brain Research 
Behav Neural Biol   Behavioral and Neural Biology 
Biochem Biophys Res Commun Biochemical and Biophysical Research 
Communications 
Biol Psychiatry   Biological Psychiatry 
Biol Rev Camb Philos Soc  Biological Reviews of the Cambridge Philosophical  
Society 
Brain Res    Brain Research 
Brain Res Bull   Brain Research Bulletin 
Can J Neurol Sci   Canadian Journal of Neuroscience 
Cell Tissue Res   Cell and Tissue Research 
Cereb Cortex    Cerebral Cortex 
Child’s Nerv Syst   Child’s Nervous System 
Eur J Neurosci   European Journal of Neuroscience 
Exp Neurol    Journal of Experimental Neurology 
Exp Neurosci    Journal of Experimental Neuroscience 
Harb Perspect Med   Cold Spring Harbor Perspectives in Medicine 
 79 
J Comp Neurol   Journal of Comparative Neurology 
J Gene Med    Journal of Gene Medicine 
J Histochem Cytochem  Journal of Histochemistry and Cytochemistry 
J Neurochem    Journal of Neurochemistry 
J Neurosci    Journal of Neuroscience 
J Physiol    Journal of Physiology 
Mol Brain Res    Molecular Brain Research 
Mol Cell Neurosci   Molecular and Cellular Neuroscience 
Mol Pharamacol   Molecular Pharmacology 
N Engl J Med    New England Journal of Medicine 
Nat Neurosci    Nature Neuroscience  
Nat Protoc    Nature Protocols  
Neural Netw    Neural Networks 
Neurobiol Dis    Neurobiology of Disease 
Neurobiol Learn Mem  Neurobiology of Learning and Memory 
Neurochem Res   Neurochemistry Research 
Neurol Clin    Neurologic Clinics 
Neurosci    Neuroscience 
Neurosci Lett    Neuroscience Letters 
NMR Biomed    NMR in Biomedicine 
Pharmacol Ther B   Pharmacology and Therapeutics Part B  
 80 
Proc Natl Acad Sci USA  Proceedings of the National Academy of Science of 
the United States of America 
Prog Brain Res   Progress in Brain Research 
Trends Neurosci   Trends in Neuroscience  
Trends Pharmacol Sci   Trends in Pharmacological Sciences 
Transgenic Res   Transgenic Research 
Sci Signal    Science Signaling 
  
 81 
REFERENCES 
 
Arai, R., Karasawa, N., Geffard, M., Nafatsu, I. 1995. L-Dopa is converted to dopamine 
in serotonergic fibers of the striatum of the rat.  A double-labeling 
immunofluorescence study.  Neurosci. Lett. 195:195-198. 
Asada, H., Kawamura, Y., Maruyama, K., Kume, H., Ding, R., Ji, F.Y., Kanbara, 
N., Kuzume, H., Sanbo, M., Yagi, T., Obata, K. . 1994. Mice Lacking the 65 kDa 
Isoform of Glutamic Acid Decarboxylase (GAD65) Maintain Normal Levels of 
GAD67 and GABA in Their Brains but are Susceptible to Seizures. Biochem 
Biophys Res Commun., 229(3):891-5. 
Arias-Montaño JA, Floran B, Floran L, Aceves J, Young JM.2007. Dopamine D(1) 
receptor facilitation of depolarization-induced release of gamma-amino-butyric 
acid in rat striatum is mediated by the cAMP/PKA pathway and involves P/Q-
type calcium channels. Synapse. 2007 May;61(5):310-9. 
Aubert, I., Guigoni, C., Hakansson, K.. 2005. IncreasedD1 dopamine receptor signaling 
in levodopa-induced dyskinesia. Ann. Neurol., 57:17-26. 
Banke, T.G., Bowie, D., Lee, H., Huganir, R.L., Schousboe, A., Traynelis, S.F. 2000. 
Control of GluR1 AMPA receptor function by cAMP-dependent protein kinase. J. 
Neurosci., 20:89-102. 
Bateup HS, Santini E, Shen W, Birnbaum S, Valjent E, Surmeier DJ, Fisone G, Nestler 
EJ, Greengard P. 2010. Distinct subclasses of medium spiny neurons 
differentially regulate striatal motor behaviors. Proc Natl Acad Sci U S A, 
107(33):14845-50. 
Berardelli, A., Rothwell, J.C., Thompson, P.D., Hallett, M. 2001. Pathophysiology of 
bradykinesia in Parkinson's disease. Brain, 124(11):2131-2146. 
Berthet, A., Porras, G., Doudnikoff, E., Stark, H., Cador, M., Bezard, E., Bloch, B. 2009. 
Pharmacological analysis demonstrates dramatic alteration of D1 dopamine 
receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia. J. 
Neurosci., 29:4829-4835. 
Bibbiani, F., Oh, J.D., Petzer, J.P., Castagnoli Jr., N., Chen, J.F., Schwarzschild, M.A.., 
Chase, T.N. 2003. A2A antagonist prevents dopamine agonist-induced motor 
complications in animal models of Parkinson's disease. Exp. Neurol., 184: 285–
294. 
 82 
Bido, S., Marti, M., Morari, M. 2011. Amantadine attenuates levodopa-induced 
dyskinesia in mice and rats preventing the accompanying rise in nigral GABA 
levels. J. Neurochem., 118:1043-1055.  
Bliss, T.V., Lomo, T.1973. Long-lasting potentiation of synaptic transmission in the 
dentate area of the anaesthetized rabbit following stimulation of the perforant 
path. J. Physiol., 232(2):331-56. 
Bolam, J.P., Freund, T.F., Björklund, A., Dunnett, S.B., Smith, A.D.1985. Synaptic input 
and local output of dopaminergic neurons in grafts that functionally reinnervate 
the host neostriatum. Exp Brain Res. 68(1):131-46. 
Bonci, A., Hopf, F.W., 2005. The dopamine D2 receptor: new surprises from an old 
friend. Neuron, 47(3):335-8. 
Brasted, P..J., Wise, S.P. 2004; Comparison of learning-related neuronal activity in the 
dorsal premotor cortex and striatum. Eur J Neurosci., 19(3):721-40. 
Brooks, S.P., Dunnett, S.B. 2009. Tests to assess motor phenotype in mice: a user’s 
guide. Nature Reviews Neuroscience, 10: 519-529.   
Bureau, G., Carrier, M., Lebel, M., Cyr, M. 2010. Intrastriatal inhibition of extracellular 
signal-regulated kinases impaired the consolidation phase of motor skill learning. 
Neurobiol Learn Mem., 94(1):107-15. 
Calabresi, P., Maj, R., Pisani, A., Mercuri, N.B., Bernardi, G. 1992. Long-term synaptic 
depression in the striatum: Physiological and pharmacological characterization. J.  
Neurosci., 12:4224-4233.  
Calabresi, P., Pisani, A., Mercuri, N.B., Bernardi, G. 1994. Post-receptor mechanisms 
underlying striatal long-term depression. J Neurosci. 14(8):4871-81. 
Calabresi, P., Gubellini, P., Centonze, D., Picconi, B., Bernardi, G., Chergui, K., 
Svenningsson, P., Fienberg, A.A., Greengard, P. 2000. Dopamine and cAMP-
regulated phosphoprotein 32 kDa controls both striatal long-term depression and 
long-term potentiation, opposing forms of synaptic plasticity. J 
Neurosci. 20(22):8443-51. 
Carlsson, T., Carta, M., Winkler, C., Bjorklund, A., Kirik, D., 2007. Serotonin neuron 
transplants exacerbate L-Dopa-induced dyskinesias in a rat model of Parkinson’s 
disease. J. Neurosci., 27:8011-8022. 
Carta, A.R., Pinna,A., Cauli, O., Morelli, M. 2002. Differential regulation of GAD67, 
enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A 
 83 
receptor blockade plus L-dopa in dopamine-denervated rats. Synapse, 44(3):166-
174. 
Carta A.R., Tabrizi M.A., Baraldi P.G., Pinna A., Pala P., Morelli M.(2003). Blockade of 
A2A receptors plus L-DOPA after nigrostriatal lesion results in GAD67 changes 
different from L-DOPA alone in the rat globus pallidus and substantia nigra 
reticulata. Exp. Neurol. 184:679-687. 
Carta, M., Carlsson, T., Kirik, D., Bjorklund, A. 2007. Dopamine released from 5-HT 
terminals is the cause of L-Dopa-induced dyskinesia in parkinsonian rats. Brain. 
130:1819-1833. 
Carta, A.R., Frau, L., Pinna, A., Morelli, M. 2010. Dyskinetic potential of dopamine 
agonist is associated with different striatonigral/striatopallidal zif-268 expression. 
Exp. Neurol., 224:395-402. 
Cenci, M.A., Lee, C.S., Bjorklund, A. 1998. L-DOPA induced dyskinesia in the rat is 
associated with striatal overexpression of prodynorphin and glutamic acid 
decarboxylase mRNA. Eur. J. Neurosci, 10:2694-2706. 
Cenci, M.A., Lundbald, M.  2006. Post- versus presynaptic plasticity in L-DOPA-induced 
dyskinesia. J Neurochem., 99(2):381-92. 
Cenci, M.A. 2007. Dopamine dysregulation of movement control in L-DOPA induced 
dyskinesia. Trends Neurosci, 30:236-243. 
Cerovic, M., d’Isa, R., Tonini, R., Brambilla, R. 2013. Molecular and cellular 
mechanisms of dopamine-mediated behavioral plasticity in the striatum. 
Neurobiology of Learning and Memory, 105:63-80. 
 Charpier, S., Deniau, J.M. 1997. In vivo activity-dependent plasticity at corticostriatal 
connections: Evidence for physiological long-term potentiation.  Proc. Natl. 
Acad. Sci. U. S.A., 94:7036-7040. 
Charpier, S., Mahon, S., Deniau, J.M. 1999. In vivo induction of striatal long-
termpotentiation by low-frequency stimulation of the cerebral cortex. Neurosci., 
91(4):1209-22. 
Choi, K.H., Clements, R.L., Greenshaw, A.J. 2005. Simultaneous 
AMPA/kainate receptor blockade and dopamine D(2/3) receptor stimulation in 
the nucleus accumbens decreases brain stimulation reward in rats. Behav Brain 
Res., 158(1):79-88. 
Corvol, J.C., Muriel, M.P., Valjent, E., Feger, J., Hanoun, N., Girault, J.A., Hirsch, E.C., 
Herve, D. 2004. Persistent increase in olfactory type G-protein alpha subunit 
 84 
levels may underlie D1 receptor functional hypersensitivity in Parkinson disease. 
J. Neurosci., 24:7007-7014. 
Corvol, J.C., Studler, J.M., Schonn, J.S., Girault, J.A., Herve, D. 2001. Galpha(olf) is 
necessary for coupling D1 and A2a receptors to adenylyl cyclase in the striatum. 
J. Neurochem., 76:1 585–1588 
Cotzias, G., Papavasiliou, P.S., Gellene, R. 1969. Modification of Parkinsonism — 
Chronic Treatment with L-Dopa. N Engl J Med., 280(7):337-45. 
Coune, P. G., Craverio, M., Gaugler, M. N., Mlynarik, V., Schneider, B.L., Aebisher, P., 
Gruetter, R. 2012. An in vivo ultrahigh field 14.1T1 H-MRS study on 6-OHDA 
and α-synuclein-based rat models of Parkinson’s disease: GABA as an early 
disease marker. NMR Biomed, 26: 43-50. 
Crittenden, J.R., Cantuti-Castelvetri, I., Saka, E., Keller-McGandy, C.E., Hernandez, 
L.F., Kett, L.R., Young, A.B., Standaert, D.G., Graybie, A.M. 2009. 
Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of 
motor side-effects induced by anti-parkinsonian therapy. Proc. Natl. Acad. Sci. U. 
S.A., 106:2892–2896.  
Cui, G., Jun, S., Jin, X., Pham, M.D., Vogel, S.S., Lovinger, D.M., Costa, R.M. 2013. 
Concurrent activation of striatal direct and indirect pathways during action 
initiation. Nature, 494:238-242. 
Cuzon Carlson, V.C., Mathur, B.N., Davis, M.I., Lovinger, D.M. 2011. Subsets of Spiny 
Striosomal Striatal Neurons Revealed in the Gad1-GFP BAC Transgenic Mouse. 
Basal Ganglia, 1(4):201-211. 
Day, M., Wang, Z., Ding, J. 2006. Selective elimination of glutamatergic synapses on 
striatopallidal neurons in Parkinson disease models. Nat. Neurosci., 9: 251–259. 
DeLong, M.R., Wichmann,, T. 2007. Circuits and circuit disorders of the basal ganglia. 
Arch Neurol., 64(1):20-24. 
Devan, B.D., McDonald, R.J., White, N.M. 1999. Effects of medial and lateral caudate-
putamen lesions on place- and cue-guided behaviors in the water maze: relation to 
thigmotaxis. Behavioral Brain Research, 100:5-14.  
Devan, B.D., White, N.M. 1999. Parallel information processing in the dorsal striatum: 
relation to hippocampal function. J. Neurosci., 19(7):2789-98. 
Dunnett, S.B., Robbins, T.W. 1992. The functional role of mesotelencephalic dopamine 
systems. Biol Rev Camb Philos Soc., 67(4):491-518. 
 85 
Ehringer, H., Hornykiewicz, O. 1960. Distribution of noradrenaline and dopamine (3-
hydroxytyramine) in the human brain and their behavior in diseases of the 
extrapyramidal system. Klin Wochenschr, 38:1236-9. 
Esclapez, M., Tillakaratne, N.J., Kaufman, D.L., Tobin, A.J, Houser CR.1994. 
Comparative localization of two forms of glutamic acid decarboxylase and their 
mRNAs in rat brain supports the concept of functional differences between the 
forms. J Neurosci., 14(3 Pt 2):1834-55. 
Erlander, M.G., Tobin, A.J. 1991. The structural and functional heterogeneity of glutamic 
acid decarboxylase: a review. Neurochem Res., 16(3):215-26. 
Fahn, S. 2003. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad 
Sci., 991:1-14. 
Fasano, S., Bezard, E., D’Antoni, A. 2010. Inhibition of Ras-guanine nucleotide-
releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms 
associated with L-dopa-induced dyskinesia. Proc. Natl. Acad. Sci. U. S. A.., 107: 
21824–21829. 
Ferguson, S.M., Phillips, P.E., Roth, B.L., Wess, J., Neumaier, J.F. 2013. Direct-pathway 
striatal neurons regulate the retention of decision-making strategies. J 
Neurosci., 33(28):11668-76. 
Fink, J.S., Weaver, D.R., Rivkees, S.A., Peterfreund, R.A., Pollack, A.E., Adler, E.M., 
Reppert, S.M. 1992. Molecular cloning of the rat A2 adenosine receptor: selective 
co-expression with D2 dopamine receptor in rat striatum. Mol. Brain Res., 
14:186-195. 
Fiorentini, C., Rizzetti, M.C., Busi, C., Bontempi, S., Collo, G., Spano, P., Missale, C. 
2006. Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor 
complexes in L-DOPA-induced dyskinesia in the rat. Mol. Pharmacol., 69: 805–
812. 
Fino, E., Glowinski, J., Venance, L. 2005. Bidirectional activity-dependent plasticity at 
corticostriatal synapses. J. Neurosci., 25(49):11279-87. 
Fisone, G., Bezard, E. 2011. Molecular mechanisms of L-Dopa induced dyskinesia. 
International Review of Neurobiology, 98: 95-122. 
Francardo, V., Recchia, A., Popovic, N., Andersson, D., Nissbrant, H., Cenci, A.M. 2011. 
Impact of the lesion procedure on the profiles of motor impairment and molecular 
responsiveness to L-Dopa in the 6-hydroxydopamine mouse model of Parkinson’s 
disease. Neurobiology of Disease, 42:327-340. 
 86 
Frau, L., Morelli, M., Simola, N. 2013. Performance of movement in hemiparkinsonian 
rats influences the modifications induced by dopamine agonists in striatal efferent 
dynorphinergic neurons. Experimental Neurology, 247:663-672. 
Frau, R., Pillolla, G., Bini, V., Tambaro, S., Devoto, P., Bortolato, M. 2013. Inhibition of 
5α-reductase attenuates behavioral effects of D1-, but not D2-like receptor 
agonists in C57BL/6 mice. Psychoneuroendocrinology, 38(4):542-51. 
Gerfen, C.R., Engber, T.M., Mahan, L.C., Susel, Z., Chase, T.N., Monsma, F.J., Sibley, 
D.R. 1990. D1 and D2 dopamine receptor-regulated gene expression of 
striatonigral and striatopallidal neurons. Science. 250:1429-32. 
Gerfen, C.R. 1992. The neostriatal mosaic: multiple levels of compartmental 
organization. Trends Neurosci., 15(4):133-9. 
Gerfen CR, Engber TM.1992. Molecular neuroanatomic mechanisms of Parkinson's 
disease: a proposed therapeutic approach. Neurol Clin. 10(2):435-49. 
Gerfen, C.R., Paletzki,R., Worley, P. 2008. Differences between dorsal and ventral 
striatum in Drd1a dopamine receptor coupling of dopamine- and cAMP-regulated 
phosphoprotein-32 to activation of extracellular signal-regulated kinase. J. 
Neurosci., 28:7113–7120. 
Gerfen, C.R., Surmeier, D.J. 2011. Modulation of striatal projection systems by 
dopamine. Annual Review of Neuroscience, 118:740-750. 
Gold, S.J., Hoang, C.V., Potts, B.W. 2007. RGS9-2 negatively modulates L-3,4-
dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease. 
J. Neurosci.., 27: 14338–14348. 
Goldman-Rakic, P.S., Porrino, L.J. 1985. The primate mediodorsal (MD) nucleus and its 
projection to the frontal lobe. J Comp Neurol., 242(4):535-60. 
Goto Y, Otani S, Grace AA. 2007. The Yin and Yang of dopamine release: a new 
perspective. Neuropharmacology, 53(5):583-7. 
Grace, 2007. Regulation of firing of dopaminergic neurons and control of goal-directed 
behaviors. Trends Neurosci., 30(5):220-7. 
Greengard, P. 2001. The neurobiology of slow synaptic transmission. Science, 
294(5544):1024-30 
Grueter, B.A., Brasnjo, G., Malenka, R.C. 2010. Postsynaptic TRPV1 triggers cell type-
specific long-term depression in the nucleus accumbens.  Nat. Neurosci., 1:1519-
1525. 
 87 
Guigoni, C., Doudnikoff, E., Li, Q., Bloch, B., Bezard, E. 2007. Altered D1 dopamine 
receptor trafficking in parkinsonian and dyskinetic non-human primates. 
Neurobiol. Dis., 26:452-463. 
Haber, S., Calzavara, R. 2009. The cortico-basal ganglia integrative network: The role of 
the thalamus. Brain Res. Bull., 78:69-74. 
Hallett, P.J., Dunah,  A.W., Ravenscroft, P., Zhou, S., Bezard, E., Crossman, A.R., 
Brotchie, J.M., Standaert, D.G.. 2005. Alterations of striatal NMDA receptor 
subunits associated with the development of dyskinesia in the MPTP-lesioned 
primate model of Parkinson's disease. Neuropharmacology, 48:503–516. 
Heimer, L., Wilson, R. D. 1975."The subcortical projections of the allocortex: 
Similarities in the neural connections of the hippocampus, the piriform cortex and 
the neocortex". In Santini, Maurizio. Golgi Centennial Symposium Proceedings. 
New York: Raven. pp. 177–193. 
Herrero, M., Barcia, C., Navarro, J. 2002. Functional anatomy of thalamus and basal 
ganglia. Child’s Nerv. Syst., 18:386-404. 
Heusner, C.L., Beutler, B.R., Housner, C.L.,Palmiter, R.D. 2008. Deletion of Gad67 in 
dopamine receptor-containing cells causes specific motor deficits. Genesis, 
46(7):357-367. 
Hisatsune, C., Ogawa, N., Mikoshiba, K. (2013). Striatum-specific expression of Cre 
recombinase using the Gpr88 promoter in mice. Transgenic Res., 22:1241-1247. 
Horvath, L., van Marion, I., Khalid, T., Nielsen, T.T.., Lundberg, C. 2011. Knockdown of 
GAD67 protein levels normalizes neuronal activity in a rat model of Parkinson’s 
disease. J. Gene Med., 13:188-197. 
Houk, J.C., Wise, S.P. 1995. Distributed modular architectures linking basal ganglia, 
cerebellum, and cerebral cortex: their role in planning and controlling action. 
Cereb Cortex, 5(2):95-110 
Hurley, M.J., Mash, D.C., Jenner, P. 2001. Dopamine D(1) receptor expression in human 
basal ganglia and changes in Parkinson’s disease. Mol. Brain Res., 87:271-279. 
Jancic, D., Lopez de Armentia, M., Valor, L.M., Olivares, R., Barco, A. 2011. Inhibition 
of cAMP response element-binding protein reduces neuronal excitability and 
plasticity, and triggers neurodegeneration. Cereb Cortex., 19(11):2535-47.  
Jenner, P. 2008. Molecular mechanisms of L-DOPA induced dyskinesia. Nature Reviews 
Neuroscience, 9:665-677. 
 88 
Joel, D., Weiner, I. 2000. The connections of the dopaminergic system with the striatum 
in rats and primates: an analysis with respect to the functional and compartmental 
organization of the striatum. Neuroscience, 96: 451-474. 
Jog, M.S., Kubota, Y., Connolly, C.I., Hillegaart, V., Graybiel, A.M. 1999. Building 
neural representations of habits. Science, 286(5445):1745-9. 
Kannari, K., Yamato, H., Shen, H., Tomiyama, M., Suda, T., Matsunaga, M. 2001. 
Activation of 5-HT(1A) but not 5-HT (1B) receptors attenuates an increase in 
extracellular dopamine derived from exogenously administered L-DOPA in the 
striatum with nigrostriatal denervation. J. Neurochem., 76:1346-1353. 
Katz, J., Nielsen, K.M., Soghomonian, J.J. 2005. Comparative effects of acute or chronic 
administration of levodopa to 6-hydroxydopamine-lesioned rats on the expression 
of glutamic acid decarboxylase in the neostriatum and GABAA receptors subunits 
in the substantia nigra, pars reticulata. Neuroscience, 132:883-842. 
Kawagoe, R., Takikawa, Y., Hikosaka, O.1998. Expectation of reward modulates 
cognitive signals in the basal ganglia. Nat Neurosci. 1(5):411-6. 
Kelly, R.M., Strick, P.L. 2004. Macro-architecture of basal ganglia loops with the 
cerebral cortex: use of rabies virus to reveal multisynaptic circuits. Prog Brain 
Res., 143:449-459. 
Kita, H., Kosaka, T., Heizmann, C.W. 1990. Parvalbumin-immunoreactive neurons in the 
rat neostriatum: a light and electron microscopic study. Brain Res, 536(1-2):1-15. 
Kolomiets, B.P., Deniau, J.M., Mailly, P., Ménétrey, A., Glowinski, J., Thierry, A.M. 
2001. Segregation and convergence of information flow through the cortico-
subthalamic pathways. J Neurosci. 21(15):5764-72. 
Konitsiotis, S., Blanchet, P.J., Verhagen, L., Lamers, E., Chase, T.N. 2000. AMPA 
receptor blockade improves leveodopa-induced dyskinesia in MPTP monkeys. 
Neurology, 54:1589-1595. 
Konstantinos, P., Kurz, M.J., Lau, Y. 2009. Restorative effect of endurance exercise on 
behavioral deficits in the chronic mouse model of Parkinson's disease with severe 
neurodegeneration. BMC Neuroscience, 10:6. 
Kreitzer, A.C. 2009. Physiology and pharmacology of striatal neurons. Annu Rev 
Neurosci.,32:127-147. 
Kumar, U. 2008. Somatostatin in medium-sized aspiny interneurons of striatum is 
responsible for their preservation in quinolinic acid and N-methyl-D-asparate-
induced neurotoxicity. J Mol Neurosci., 35(3):345-54.  
 89 
Lanciego, J.L., Luquin, N., Obeso, J.A. 2012. Functional neuroanatomy of the basal 
ganglia. Cold Spring Harb Perspect Med., 3(12):1-21. 
Laprade N., Soghomonian, J.J. 1999. Gene expression of the GAD67 and GAD65 
isoforms of glutamate decarboxylase is differentially altered in subpopulations of 
striatal neurons in adult rats lesioned with 6-OHDA as neonates. Synapse, 
33(1):36-48. 
Lau, G., Murthy, V. N. 2012. Activity-dependent regulation of inhibition via GAD67.  J. 
Neurosci., 32(25): 8521-8531. 
Lauwereyns, J., Takikawa, Y., Kawagoe, R., Kobayashi, S., Koizumi, M., Coe, B., 
Sakagami, M., Hikosaka, O. 2002. Feature-based anticipation of cues that predict 
reward in monkey caudate nucleus. Neuron, 33(3):463-73. 
Lebel M, Robinson P, Cyr M.2010. The role of dopamine receptor function in 
neurodegenerative diseases. Can J Neurol Sci., 34(1):18-29. 
Logue, S.F., Grauer, S.M., Paulsen, J., Radka, G., Tayolr, N., Sung, M.A., Xhang, L., 
Hughes, Z., Pulito, V.L., Liu, F., Rosenzweig-Lipson, S., Brandon, N.J., Marquis, 
K.L., Bates, B., Pausch, M. (2009). The orphan GPCR, GPR88, modulates 
function of the striatal dopamine system: A possible therapeutic target for 
psychiatric disorders? Mol Cell Neurosci., 42:438-447. 
Lovinger, D.M. 2012. New twist on orphan receptor GPR88 function. Nat Neurosci, 
15:1469-1470. 
Lindefors, N., Brene, S., Herrera-Marschitz, M., Persson, H. 1989. Region specific 
regulation of glutamic acid decarboxylase mRNA expression by dopamine 
neurons in rat brain. Exp Brain Res., 77(3):611-20. 
Linderfors, N. 1993. Dopaminergic regulation of glutamic acid decarboxylase mRNA 
expression and GABA release in the striatum: a review. Progress in Neuro-
psychopharmacological Biology and Psychiatry 7(6):887-903. 
Lindgren, H.S., Andersson, D.R., Lagerkvist, S., Nissbrandt, H., Cenci, M.A. 2010. L-
DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat 
model of Parkinson's disease: temporal and quantitative relationship to the 
expression of dyskinesia. J. Neurochem., 112(6):1465-76. 
Lovinger, D.M. 2010. Neurotransmitter roles in synaptic modulation, plasticity and 
learning in the dorsal striatum. Neuropharmacology, 58(7):951-61. 
Mangiavacchi, S., Wolf, M.E. 2004. Stimulation of N-methyl-D-aspartate receptors, 
AMPA receptors or metabotropic glutamate receptors leads to rapid 
 90 
internalization of AMPA receptors in cultured nucleus accumbens neurons. Eur J 
Neurosci., 20(3):649-57. 
Massart, R., Guilloux, J.P., Mignon, V., Sokoloft, P., Diaz, J. (2009). Striatal GPR88 
expression is confined to the whole projection neuron population and is regulated 
by dopaminergic and glutamatergic afferents. Eur J Neurosci., 30:397-414. 
McDonald, R.J., White, N.M. 1994. Parallel information processing in the water maze: 
evidence for independent memory systems involving dorsal striatum and 
hippocampus. Behav Neural Biol., 61(3):260-70. 
Mela, F., Marti, M., Dekundy, A., Danysz, W., Morari, M., Cenci, M.A. 2007. 
Antagonism of metabotropic glutamate receptor type 5attenuates L-DOPA 
induced dyskinesia and its molecular and neurochemical correlates in a rat model 
of Parkinson’s disease. J. Neurochem., 101:483-497. 
Mela, F., Marti, M., Dekundy, A., Danysz, W., Morari, M., Cenci, M.A., 2007. 
Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA 
induced-dyskinesia and its molecular and neurochemical correlates in a rat model 
of Parkinson’s disease. J. Neurochem, 101:483-497.  
Mercuri, N.B., Bernardi, G. 2005. The 'magic' of L-dopa: why is it the gold standard 
Parkinson's disease therapy? Trends Pharmacol Sci., 26(7):341-4. 
Mink, J.W. 2003. The basal ganglia and involuntary movements: impaired inhibition of 
competing motor patterns.  Archives of Neuroscience, 60:1365-1368.  
Miyachi, S., Hikosaka, O., Lu, X. 2002. Differential activation of monkey striatal 
neurons in the early and late stages of procedural learning. Exp Brain Res., 
146(1):122-6. 
Nakano, K., Hasegawa, Y., Tokushige, A., Nakagawa, S., Kayahara, T., Mizuno, N. 
1990. Topographical projections from the thalamus, subthalamic nucleus and 
pedunculopontine tegmental nucleus to the striatum in the Japanese monkey, 
Macaca fuscata. Brain Res. 537(1-2):54-68. 
Nambu, A. 2008. Seven problems on the basal ganglia.  Current Opinion in 
Neurobiology, 18:595-604. 
Nava Asbell, C., Paz-Bermudez F, Erlij D, Aceves J, Florán B. 2007 GABA(B) receptor 
activation inhibits dopamine D1 receptor-mediated facilitation of [(3)H]GABA 
release in substantia nigra pars reticulata. Neuropharmacology. 53(5):631-7. 
Obeso, J.A., Rodriguez-Oroz, M., Marin, C., Alonso, F., Zamarbide, I., Lanciego, J.L., 
Rodriguez-Diaz, M. 2004. The origin of motor fluctuations in Parkinson's disease: 
 91 
importance of dopaminergic innervation and basal ganglia circuits. Neurology, 
62:S17-30. 
Packard, M.G., and Knowlton, B.J. 2002. Learning and memory functions of the Basal 
Ganglia. Annu Rev Neurosci., 25:563-93. 
Parent, A., Hazrati, L. 1995. Functional anatomy of the basal ganglia. I. The cortico-basal 
ganglia-thalamo-cortical loop. Brain Research Reviews, 20:91-127. 
Perier, C., Bové, J., Vila, M., Przedborski, S. 2003. The rotenone model of Parkinson's 
disease. Trends Neurosci., 26(7):345-6. 
Picconi, B., Centonze, D., Håkansson, K., Bernardi, G., Greengard, P., Fisone, G., Cenci, 
M.A., Calabresi, P. 2003. Loss of bidirectional striatal synaptic plasticity in L-
DOPA-induced dyskinesia. Nat Neurosci., 6(5):501-6. 
Quiroz, C.,Lujan, R., Uchigashima, M. 2009. Key modulatory role of presynaptic 
adenosine A2A receptors in cortical neurotransmission to the striatal direct 
pathway. ScientificWorldJournal, 9: 1321–1344. 
Rahman, Z., Schwarz, J., Gold, S.J. 2003. RGS9 modulates dopamine signaling in the 
basal ganglia. Neuron, 38: 941–952. 
Rangel-Barajas, C., Silva I, García-Ramírez M, Sánchez-Lemus E, Floran L, Aceves 
J, Erlij D, Florán B.2008. 6-OHDA-induced hemiparkinsonism and chronic L-
DOPA treatment increase dopamine D1-stimulated [(3)H]-GABA release and 
[(3)H]-cAMP production in substantia nigra pars reticulata of the rat. 
Neuropharmacology., 55(5):704-11. 
Rangel-Barajas, C., Silva, I., Lopez-Santiago, L.M., Aceves, J., Erlij, D., Floran, B. 2011. 
L-dopa induced dyskinesia in hemiparkinsonian rats is associated with up-
regulation of adenylyl cyclase type V/VI and increased GABA release in the 
substantia nigra reticulata. Neurobiology of Disease, 41:51-61. 
Reynolds, J.N., Wickens, J.R. 2002. Dopamine-dependent plasticity of corticostriatal 
synapses. Neural Netw. 15:507-21. 
Rylander, D., Iderberg, H., Li, Q. 2010. A mGluR5 antagonist under clinical 
development improves L-DOPA induced dyskinesia in parkinsonian rats and 
monkeys. Neurobiol. Dis., 39:352-361. 
Sadikot, A.F., Parent, A., Smith, Y., Bolam, J.P. 1992. Efferent connections of the 
centromedian and parafascicular thalamic nuclei in the squirrel monkey: a light 
and electron microscopic study of the thalamostriatal projection in relation to 
striatal heterogeneity. J Comp Neurol., 320(2):228-42. 
 92 
Santini, E., Valjent, E., Usiello, A. Carta, M., Borgkvist, A., Girault, J.A., Herve, D., 
Greengard, P., Fisone, G. 2007. Critical involvement of cAMP/DARPP-32 and 
extracellular signal-regulated protein kinase signaling in L-DOPA-induced 
dyskinesia. J. Neurosci.,, 27: 6995–7005. 
Santini, E., Heiman, M., Greengard, P., Valjent, E., Fisone, G. 2009. Inhibition of mTOR 
signaling in Parkinson’s disease prevents L-DOPA induced dyskinesia. Sci. 
Signal, 2:ra36. 
Schober, A. (2004). Classic toxin-induced animal models of Parkinson’s disease: 6-
OHDA and MPTP. Cell Tissue Res,18(1):215-24.  
Schuster, S., Nadjar, A., Guo, J.T., Li, Q., Ittrich, C., Hengerer, B., Bezard, E.. 2008. The 
3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity 
of L-DOPA-induced abnormal involuntary movements in experimental 
Parkinson's disease. J. Neurosci., 28:4311–4316. 
Schuster, S., Doudnikoff, E., Rylander, D. 2009. Antagonizing L-type Ca2+ channel 
reduces development of abnormal involuntary movement in the rat model of L-
3,4-dihydroxyphenylalanine-induced dyskinesia. Biol. Psychiatry, 65:518–526. 
Segovia, J., Tillakaratne, N.J., Whelan, K., Tobin, A.J., Gale, K.. 1990. Parallel in 
increases in striatal glutamic acid decarboxylase activity and mRNA levels in rats 
with lesions of the nigrostriatalpathway. Brain Res., 529(1-2):345-8. 
Sheikh, S.N., Martin, D.L. 1998. Elevation of brain GABA levels with vigabatrin 
(gamma-vinylGABA) differentially affects GAD65 and GAD67 expression in 
various regions of rat brain. J Neurosci Res., 52(6):736-41. 
Silverdale, M.A., Kobylecki, C., Hallett, P.J., Li, Q., Dunah, A.W., Ravenscroft, P., 
Bezard, E., Brotchie, J.M. 2010. Synaptic recruitment of AMPA glutamate 
receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned 
nonhuman primate. Synapse, 64:177-180. 
Smith, Y., Raju, D.V., Pare, J.F., Sidibe, M..2004. The thalamostriatal system: a highly 
specific network of the basal ganglia circuitry. Trends Neurosci., 27(9):520-7.  
Smith, K.S., Graybiel AM.2013. A dual operator view of habitual behavior reflecting 
cortical and striatal dynamics. Neuron, 79(3):608. 
Soghomonian, J.J., Chesselet, M.F. 1992. Effects of nigrostriatal lesions on the levels of 
messenger RNAs encoding two isoforms of glutamate decarboxylase in the 
globus pallidus and entopeduncular nucleus of the rat. Synapse, 11(2):124-33. 
 93 
Soghomonian, J.J., Martin, D.L. 1998. Two isoforms of glutamate decarboxylase: why? 
Trends Pharmacol Sci., 19(12):500-5. 
Stoof, J.C., Kebabian, J.W. 1981. Opposing roles for D-1 and D-2 dopamine receptors in 
efflux of cyclic AMP from rat neostriatum. Nature. 294(5839):366-8. 
Tepper, J.M., Tecuapetia, F., Koos, T., Ibanez-Sandoval, O. 2010. Heterogeneity and 
diversity of striatal GABAergic interneurons. Frontiers in Neuroanatomy, 4:150. 
Tian, N., Petersen ,C., Kash, S., Baekkeskov, S., Copenhagen, D., Nicoll, R. 1999. The 
role of the synthetic enzyme Gad65 in the control of neuronal gamma-
aminobutyric acid release. Proc Natl Acad Sci U S A., 96(22):12911-6. 
Trifonov, S., Houtani, T., Kase, M., Toida, K., Maruyama, M., Yamashita, Y., Shimizu, 
J., Sugimoto, T. 2012. Lateral regions of the rodent striatum reveal elevated 
glutamate decarboxylase 1 mRNA expression in medium-sized projection 
neurons. Eur J Neurosci., 35(5):711-22. 
Ungerstedt, U. 1976. 6-hydroxydopamine-induced degeneration of the nigrostriatal 
dopamine pathway: the turning syndrome. Pharmacol Ther B, 2(1):47-40. 
Valjent, E., Pascoli, V., Svenningsson, P. 2005. Regulation of a protein phosphatase 
cascade allows convergent dopamine and glutamate signals to activate ERK in the 
striatum. Proc. Natl. Acad. Sci. U. S. A.., 102: 491–496. 
Van der Loos, C.M. (2008). Multiple Immunoenzyme Staining: Methods and 
visualizations for the observation with spectral imaging. J Histochem Cytochem, 
56(4): 313-328. 
Voorn, P., Vanderschuren, L.J., Groenewegn, H.J, Robbins, T.W., Pennartz, C.M. 2004. 
Putting a spin on the dorsal-ventral divide of the striatum. Trends in 
Neuroscience, 27(8):468-474. 
Vorhees, C.V., Williams, M.T. 2006.Morris water maze: procedures for assessing spatial 
and related forms of learning and memory. Nat Protoc., 1(2):848-58. 
Waes, V.V., Tseng, K.Y., Steiner, H. (2011). Gpr88 – a putative signaling molecule 
predominantly expressed in the striatum: Cellular localization and developmental 
regulation.  Basal Ganglia, 1(2):83-89. 
Wang, H., Katz, J., Dagostino, P., Soghomonian, J.J. 2007. Unilateral 6-
hydroxydopamine lesion of dopamine neurons and subchronic L-Dopa 
administration in the adult rat alters the expression of the vesicular GABA 
transporter in different subsets of striatal neurons and in the substantia nigra, pars 
reticulata. Neuroscience, 145:727-737. 
 94 
Whishaw, I.Q., Mittleman G., Bunch S.T., Dunnett, S.B. 1985. Impairments in the 
acquisition, retention and selection of spatial navigation strategies after medial 
caudate-putamen lesions in rats. Behav Brain Res., 24(2):125-38. 
Wilson, C.J., Kawaguchi, Y.1996. The origins of two-state spontaneous membrane 
potential fluctuations of neostriatal spiny neurons. J. Neurosci., 16(7):2397-410. 
Woolley, D.G., Laeremans, A., Gantois, I., Mantini, D., Vermaercke, B., Op de Beeck, 
H.P., Swinnen, S.P., Wenderoth, N., Arckens, L., D'Hooge, R.2013. Homologous 
involvement of striatum and prefrontal cortex in rodent and human water maze 
learning. Proc Natl Acad Sci U S A, 110(8):3131-6.  
Yamamoto, N., Pierce, C., Soghomonian, J.J. 2006. Subchronic administration of L-
DOPA to adult rats with a unilateral 6-hydroxydopamien lesion of dopamine 
neurons results in a sensitization of enhanced GABA release in the substantia 
nigra, pars reticulate. Brain Res., 1123(1):196-200. 
Yamamoto N., Soghomonian, J.J. 2008. Time-course of SKF-81297-induced increase in 
glutamic acid decarboxylase 65 and 67 mRNA levels in striatonigral neurons and 
decrease in GABAA receptor α1 subunit mRNA levels in the substantia nigra, pars 
reticulate, in adult rats with a unilateral 6-hydroxydopamine lesion. Neuroscience, 
154:1088-1099. 
Yamamoto, N., Soghomonian, J.J. 2009. Metabotropic glutamate mGluR5 receptor 
blockade opposes abnormal involuntary movements and the increases in glutamic 
acid decarboxylase mRNA levels induced by L-Dopa in striatal neurons of 6-
hydroxydopamine-lesioned rats. Neuroscience, 163:1171-1180. 
Yin, H.H., Knowlton, B.J. 2006. The role of the basal ganglia in habit formation. Nat Rev 
Neurosci., 7(6):464-76. 
Zigmond, M.J., Abercrombie, E.D., Berger, T.W., Grace, A.A., Stricker, E.M. 1990. 
Compensations after lesions of central dopaminergic neurons: some clinical and 
basic implications. Trends Neurosci, 13(7):290-296. 
 
  
 95 
 
CURRICULUM VITAE 
 96 
 97 
